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Abstract 
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   Chronic inflammation is characterized by infiltration of inflammatory 
cells and persistent activation of immune system, leading to aberrant 
production of proinflammatory cytokines. Numerous studies have provided 
the evidence that proinflammatory cytokines, including TNFα, IL-6, and 
IL-23, play key roles in chronic inflammation, and many biologic drugs 
targeting these cytokines have shown excellent therapeutic effects in clinical, 
however, they still have some problems the presence of nonresponsive 
patients and a low remission rate in monotherapy. To elucidate the 
immunological mechanisms of chronic inflammation and identify potential 
targets for novel anti-inflammatory drugs, in this study, I have focused 
attention on the intracellular signaling pathway regulating proinflammatory 
cytokine production. 
In the first chapter, I have screened and identified a novel p38 MAPK 
inhibitor, AS1940477, and its anti-inflammatory effect and selectivity profile 
have been evaluated. AS1940477 selectively inhibited enzyme activity 
against p38α and β isoforms, and suppressed proinflammatory cytokine 
production in human peripheral blood mononuclear cells and signal 
activation in synovial stromal cells. AS1940477 also potently inhibited 
LPS-induced TNFα production in vivo, and its inhibitory effect was 
confirmed even after 20h of administration. 
In the second chapter, I have screened and identified two novel IL-12p40 
production inhibitors, AS2677131 and AS2795440, and functional 
characterization and target identification of these compounds have been 
performed. Interestingly, these compounds inhibited not only 
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proinflammatory cytokine production in macrophages but also 
BCR-mediated B cell activation, and a significant preventive effect was also 
confirmed on experimental arthritis in rats. In addition, PIKfyve, a class III 
lipid kinase, was identified as a target molecule by molecular biological 
analysis using photoreactive linker-conjugated probes. PIKfyve was also 
found to selectively control the binding activity of c-Rel, an NFκB family 
transcription factor, to the promoters of the target genes, IL-12p40 and 
IL-1β. 
In conclusion, the current study has demonstrated that p38 MAPK and 
PIKfyve play key roles in the development of chronic inflammation, and the 
inhibition of their kinase activity by novel small molecule inhibitors 
(AS1940477, AS2677131, and AS2795440) could be a new therapeutic 
approach for treating chronic inflammatory diseases. It is also expected that 
new molecules as anti-inflammatory drug targets will be found in future 
from PIKfyve-c-Rel pathway. 
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Abbreviations 
 
TNFα   tumor necrosis factor alpha 
IL   interleukine 
RA   rheumatoid arthritis 
DC   dendritic cell 
Th17   T helper 17 
MAPK   mitogen-activated protein kinase 
ERK   extracellular signal-regulated kinase 
JNK   c-Jun N-terminal kinase 
PIKfyve  phosphoinositide kinase, FYVE-type zinc finger  
   containing 
PI   phosphoinositide 
LPS   lipopolysaccharide 
PHA   phytohemagglutininA 
PGE2   prostaglandin E2 
PBMC   peripheral blood mononuclear cell 
SSC   synovial stromal cell 
MMP-3  metallopeptidase-3 
Con A   Concanavalin A 
IRF   interferon regulatory factor 
TNP   2,4,6-trinitrophenol 
DMF   N,N-di-methylformamide 
MALDI-TOFMS MALDI-TOF mass spectrometry 
5 
 
siRNA   small interfering RNA 
APC   allophycocyanin 
MDP   muramyldipeptide 
TLR   Toll-like receptor 
Poly(I:C)  polyinosinic-polycytidylic acid 
AIA   adjuvant-induced arthritis 
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General introduction 
 
With an expanding aging population in the world, the number of patients 
suffering from various aging-related diseases, including autoimmune 
diseases, atherosclerotic diseases, cancer, and neurodegenerative diseases, is 
predicted to increase in the future. Chronic inflammation is commonly 
associated with the development and progression of those diseases [1]. 
Chronic inflammation is characterized by infiltration with inflammatory 
cells (mononuclear cells, macrophages, lymphocytes) into the affected tissue 
and persistent activation of immune system, which consequently leads to 
aberrant productions of proinflammatory cytokines, chemokines, and 
autoantibodies.  
Numerous experimental studies have provided that the expression levels 
of proinflammatory cytokines, such as tumor necrosis factor alpha (TNFα), 
IL-1β, IL-6, IL-23, and IL-17, is strictly controlled, especially in amount, 
timing, and place of production, and positively correlated with the severity in 
many inflammatory diseases [2-4]. For instance, TNFα and IL-6 are rapidly 
released from activated macrophages and facilitate tissue inflammation, 
fibrosis and damage in rheumatoid arthritis (RA). IL-23 is also produced 
from activated macrophages and dendritic cells (DCs), and induce IL-17 
production from T helper 17 (Th17) cells important as an inflammation 
initiator in the pathogenesis of several inflammatory diseases, such as 
psoriasis. In addition to advances of understanding in biology as described 
above, recent remarkable advance in antibody engineering technology has 
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brought many biologic drugs to market [2]. 
The excellent therapeutic effect of the biologic drugs that can neutralize 
the activity of target cytokines have indicated that inflammatory cytokines 
play an important role in the development of chronic inflammatory diseases, 
while monotherapy for individual cytokines still has some problems, such as 
the presence of nonresponsive patients and a low remission rate. Another 
problem is also that biological therapy is relatively expensive and 
inconvenient compared to oral drugs. Therefore, I thought that there were 
unmet medical needs for oral drugs that could simultaneously inhibit 
multiple inflammatory cytokines and fundamentally improve the formation 
of chronic inflammation. 
As described above, inflammatory cytokines are predominantly produced 
by activated macrophages. Therefore, I focused on two different mechanisms 
regulating inflammatory cytokine production in macrophages and screened 
for small molecule inhibitors. The first is p38 mitogen-activated protein 
kinase (MAPK) as an important signal for the production of multiple 
inflammatory cytokines such as TNFα IL-1β and IL-6. The second is a 
production inhibitor of IL-12p40, a common component of IL-12 and IL-23. 
MAP kinases are serine/threonine protein kinases that include extracellular 
signal-regulated kinases (ERK), c-Jun N-terminal kinases (JNK), and p38 
isoforms [5]. Among of them, p38 isoforms are responsible for the step of 
production and activation signal of multiple proinflammatory cytokines. On 
the other hand, IL-23 containing IL-12p40 subunit as a component play a 
key role in the expansion and survival of Th17 cells, which is one of helper T 
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cell subsets. Th17 is thought to activate effector cells such as macrophages 
and B cells, thereby contributing to the promotion of chronic inflammation. 
In the first chapter, I have identified a novel p38 MAPK inhibitor 
AS1940477, and investigated the functional characteristics of AS1940477. 
Especially, the in vitro and in vivo characteristics regarding kinase 
selectivity and potency were evaluated in detail, and compared with those of 
previously reported p38 MAPK inhibitors in discussion section.  
In the second chapter, I have identified two novel IL-12p40 production 
inhibitors, AS2677131 and AS2795440, and extensively investigated their 
pharmacological characteristics. Thereby, it has been found that those 
inhibitors exert unique immunoregulatory functions, including selective 
proinflammatory cytokine inhibition and B cell activation inhibition. I have 
also identified phosphoinositide kinase, FYVE-type zinc finger containing 
(PIKfyve), a Class III phosphoinositide kinase, as a direct target molecule of 
these inhibitors by chemical biological approach. PIKfyve is one of 
mammalian lipid kinases that act on phosphoinositide (PI) and PI3P to 
generate PI5P and PI(3,5)P2, respectively [6], and involved in normal 
endosome processing and membrane trafficking, while immunological 
function of PIKfyve has remained almost unknown. So, I have explored the 
mechanism of action of PIKfyve inhibitors, and revealed a novel mechanism 
regulating cytokine production which is mediated by PIKfyve-c-Rel pathway. 
Taken together, in this study, I have obtained multiple small molecule 
compounds with different mechanisms, including p38 MAPK inhibitor 
(AS1940477) and PIKfyve inhibitors (AS2677131, AS2795440), which all 
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have shown potent anti-inflammatory activity. The results of functional 
characterization of these inhibitors have provided strong evidence that p38 
MAPK and PIKfyve play an important role in the production of 
inflammatory cytokines involved in the development of chronic inflammation. 
The inhibition of their activity was also indicated the possibility to become a 
new therapeutic approach for chronic inflammatory diseases.  
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Chapter I 
 
 
Anti-inflammatory effect and selectivity profile of AS1940477, a novel and 
potent p38 mitogen-activated protein kinase inhibitor 
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Summary 
 
Given the key role p38 MAPK plays in inflammatory responses through 
the production of cytokines and inflammatory mediators, its inhibition is 
considered a promising therapeutic strategy for chronic inflammatory 
diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, 
and chronic obstructive pulmonary disease. Here, I evaluated the 
anti-inflammatory effect and selectivity profile of the novel p38 MAPK 
inhibitor AS1940477. AS1940477 inhibited the enzymatic activity of 
recombinant p38 α and β isoforms but showed no effect against other 100 
protein kinases including p38 γ and δ isoforms. I also confirmed the 
selectivity of AS1940477 in the intracellular signaling pathway. In human 
peripheral blood mononuclear cells, AS1940477 inhibited lipopolysaccharide 
(LPS)- or phytohemagglutininA (PHA)-induced production of 
proinflammatory cytokines, including TNFα, IL-1β, and IL-6 at low 
concentrations (LPS/TNFα, IC50 = 0.45 nM; PHA/TNFα, IC50 = 0.40 nM). In 
addition, equivalent concentrations of AS1940477 that inhibited cytokine 
production also inhibited TNFα- and IL-1β-induced production of IL-6, PGE2, 
and MMP-3 in human synovial stromal cells. AS1940477 was also found to 
potently inhibit TNFα production in whole blood (IC50 = 12 nM) and 
effectively inhibited TNFα production induced by systemically administered 
LPS in rats at less than 0.1 mg/kg (ED50 = 0.053 mg/kg) with an 
anti-inflammatory effect lasting for 20 h after oral administration. Overall, 
this study demonstrate that AS1940477 is a novel and potent p38 MAPK 
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inhibitor and may be useful as a promising anti-inflammatory agent for 
treating inflammatory disorders. 
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Introduction 
 
   Chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, 
and inflammatory bowel disease are characterized by autoimmune responses, 
leading to the destruction of normal tissues [7-9]. While the underlying 
immunological mechanisms and pathogenic factors contributing to the 
initiation and development of chronic inflammatory diseases have not been 
fully elucidated, the therapeutic success of cytokine-neutralizing agents (e.g. 
infliximab, adalimumab, etanercept, anakinra, and tocilizumab) suggests 
that proinflammatory cytokines such as TNFα, IL-1β and IL-6 play a central 
role in the pathogenesis of certain inflammatory diseases [3, 4]. However, 
despite their therapeutic efficacy, these biological therapies are expensive 
and relatively inconvenient to administer, leaving an unmet need for 
developing novel anti-inflammatory therapies and more effective and orally 
available small molecule inhibitors. 
   MAPKs are serine/threonine protein kinases that include ERK, JNK, and 
p38 isoforms [5]. p38 isoforms are responsive to various cellular stress 
stimuli, including shock, inflammatory cytokines, endotoxins, and growth 
factors. To date, four isoforms (p38α, p38β, p38γ, and p38δ) have been 
identified in mammalian cells and are expressed in differential, 
tissue-specific patterns. Of these four, p38α is mainly expressed in immune 
and inflammatory cells and is associated most closely with inflammatory 
responses [10, 11] and the synthesis of a variety of proinflammatory 
mediators such as TNFα, IL-1β, IL-6, and prostaglandin E2 (PGE2) regulated 
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by p38α-dependent signaling. In addition, p38α acts downstream of TNFα 
and IL-1β [12], thereby mediating many of these molecules’ biological effects 
such as pain, cell recruitment and bone metabolism. The targeted inhibition 
of p38α using small molecule inhibitors is therefore believed to be an 
attractive strategy for treating inflammatory disorders. 
To date, many p38α inhibitors have been generated and characterized by 
a number of pharmaceutical companies, and several inhibitors, including 
BIRB796, VX-745, SCIO-469, and VX-702, have been found to exert 
beneficial effects in various animal models and have advanced to clinical 
trials. However, in light of inadequate clinical efficacy or unacceptable safety 
profiles attributed to low kinase selectivity and chemical structure-based 
toxicity, the clinical development of these compounds was eventually 
discontinued [13, 14]. 
Here, in order to evaluate a potential as an anti-inflammatory drug, I 
describe the pharmacological activity of the novel p38 inhibitor AS1940477 
and demonstrate its potent and highly selective inhibitory activity against 
p38 MAPK both in vitro and in vivo acute inflammation model. 
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Materials and Methods 
 
Preparation of AS1940477 
The p38 MAPK inhibitor AS1940477 
[6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5
-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one] was synthesized 
by Astellas Pharma (Tsukuba, Japan), and SB203580 
[4-(4-fluorophenyl)-2-(4-methylsulfinyl)-phenyl-5-(pyridin-4-yl)-1H-imidazol
e] was purchased from Sigma-Aldrich (St. Louis, MO, USA) 
 
Kinase isoform selectivity assays 
The human p38α and p38β kinase activities of AS1940477 were evaluated 
using a Z'-LyteTM kinase assay system (Life Technologies, Madison, FL, USA), 
and the activities of 99 other protein kinases (including p38γ and p38δ) were 
evaluated using a Kinase Profiling Assay (Carna Biosciences, Kobe, Japan). 
JNK2 kinase activity was examined by following an in-house protocol. 
Preactivated recombinant human JNK2α2/SAPK1a (40 ng/well; Upstate 
Biotechnology, Lake Placid, NY, USA) was diluted in 1.5× Assay Dilution 
Buffer-I (1× ADB-I; 20 mM MOPS, pH 7.2, 25 mM β-glycerol phosphate, 5 
mM EGTA, 1 mM sodium orthovanadate, 1 mM DTT), and then 20 µL of 1.5× 
ADB-I (containing recombinant JNK2) was mixed with 20 µL of Mg/ATP/1× 
ADBI buffer (37.5 mM MgCl2, 2 µM ATP diluted with 1× ADB-I) and 10 µL of 
AS1940477 at final concentrations of 10 to 1000 nM in a 96-well MaxiSorp 
Immuno Plate (Nalge Nunc International, Rochester, NY, USA) pre-coated 
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with recombinant human ATF-2 (0.1 µg/well; Upstate Biotechnology). After a 
30-min incubation at 30 °C, the plate was washed three times with 
phosphate-buffered saline buffer containing Tween 0.05% and then 
incubated with 1:1000 diluted anti-phospho-ATF-2 (Thr71) (Cell Signaling 
Technology, Danvers, MA, USA) antibody for 60 min at room temperature. 
Subsequently, the plate was washed as described above and reacted with 
1:5000 diluted anti-rabbit IgG conjugated HRP (Zymed Laboratories, South 
San Francisco, CA, USA) for 30 min at room temperature. After the plate 
was washed, TMB substrate (BD Biosciences Pharmingen, San Diego, CA, 
USA) was added, and the plate was incubated for 20 min in the dark. The 
reaction was stopped by adding 50 µL of 2 N H2SO4, and sample absorbance 
was measured with a microplate reader at 450 nm. 
 
Cellular selectivity assays using human monocytic THP-1 cells  
The selectivity of p38, JNK, and NFκB pathways in a cellular context was 
determined by measuring the phosphorylation of HSP-27 and c-Jun or IκBα 
degradation in THP-1 cells (ATCC TIB202). THP-1 cells were collected by 
centrifugation and resuspended in RPMI 1640 (Invitrogen, Carlsbad, CA, 
USA) containing 10% fetal bovine serum (BioWest, Nuaillé, France) and 1% 
(v/v) penicillin-streptomycin solution. After a 30-min pretreatment with 
AS1940477 (final concentration: 1 to 1000 nM), the cells were incubated in 
presence or absence of LPS (Escherichia coli, 055:B5, 10 µg/mL, 
Sigma-Aldrich) for 30 min at 37 °C; the reaction was stopped by adding 
ice-cold phosphate-buffered saline. The cells were collected by centrifugation, 
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lysed in 300 µL of 1× Lysis buffer (PathScan Kit contents; Cell Signaling 
Technology), sonicated for 30 sec on ice, and then centrifuged at 12,000 g for 
5 min at 4 °C. The supernatants were then stored at -80 °C until ELISA 
analysis. Phospho- and total HSP-27 (Ser78), and c-Jun (Ser63) levels were 
determined by ELISA (PathScan ELISA kit, #7290, #7145, #7150, Cell 
Signaling Technology, Immunoassay kit, #KHO0331; Biosource International, 
Camarillo, CA, USA) following the manufacturer’s instructions. Total IκBα 
amount was also determined via ELISA (Cell Signaling Technology). 
Cellular selectivity was also examined by Western blotting, THP-1 cells, 
pretreated with or without AS1940477 for 30 min, were stimulated with LPS 
(10 µg/mL) for a period of 30 min followed by a rapid lysis in RIPA buffer 
(Sigma) containing Protease and Phosphatase inhibitor (Thermo Scientific, 
Yokohama, Japan) for Western blot analysis. THP-1 cell RIPA lysates were 
evaluated for HSP-27 and c-Jun phosphorylation by Western blotting using 
phospho-specific antibodies [phospho-HSP-27 (Ser78) and phospho-c-Jun 
(Ser63)] or total recognizing antibodies [HSP-27, c-Jun, and IκBα]. All 
antibodies were purchased from Cell Signaling Technology. 
 
Inhibition of LPS- or PHA-induced cytokine production in THP-1 and human 
PBMCs 
THP-1 cells with or without 30-min AS1940477 pretreatment were 
stimulated with LPS (10 µg/mL) for 16 h, and the concentration of TNFα in 
the supernatant was determined by ELISA. Blood was collected from healthy 
volunteers into sodium heparin-treated tubes, and human peripheral blood 
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mononuclear cells (PBMCs) were isolated by Ficoll density gradient 
centrifugation using Ficoll-Paque Plus (Amersham Biosciences, Piscataway, 
NJ, USA) according to the manufacturer’s instructions. PBMCs were 
stimulated in absence or presence of AS1940477 (0.01 to 1000 nM) with LPS 
(1 µg/mL) or PHA for 16 h, and cytokine concentrations (TNFα, IL-1β, IL-6, 
and IL-10) in the medium were measured by ELISA. The following reagents 
(antibodies, standard proteins, ELISA kits) were used in the assay: purified 
mouse anti-human TNF, biotin mouse anti-human TNF, and recombinant 
human TNF (BD Biosciences Pharmingen); DuoSet human IL-1β (R&D 
Systems, Minneapolis, MN, USA); purified rat anti-human IL-6 (PeproTech, 
Rocky Hill, NJ, USA); biotin rat anti-human IL-6 and recombinant human 
IL-6 (BD Biosciences Pharmingen); purified rat anti-human IL-10 
(PeproTech); biotin anti-human and viral IL-10; and recombinant human 
IL-10 (BD Biosciences Pharmingen). 
 
Inhibition of LPS-stimulated TNFα production in human whole blood 
AS1940477 was pre-dispensed and diluted as described for the THP-1 
assay above, and human whole blood (275 µL/sample) obtained from healthy 
volunteers was incubated with diluted AS1940477 and LPS (0.01 µg/mL) for 
2 h at 37 °C. After centrifugation, the plasma concentration of TNFα was 
measured by ELISA as described above. 
 
Effect of AS1940477 on IL-6, PGE2, and MMP-3 production in human 
synovial stromal cells 
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Human Synovial Stromal Cells (SSCs) were purchased from Applied Cell 
Biology Research Institute and cultured in DMEM containing 10% fetal 
bovine serum (BioWest) and 1% (v/v) penicillin-streptomycin solution. SSCs 
pretreated with AS1940477 (0.01 to 100 nM) for 30 min were stimulated with 
or without human TNFα (1 ng/mL)/IL-1β (2 pg/mL) for 24 h, and levels of 
IL-6, PGE2, and matrix metallopeptidase-3 (MMP-3) in the medium were 
measured by ELISA as per the PBMC assay (IL-6) or following the 
manufacturer’s instructions (PGE2, EIA kit Cayman Chemical, Ann Arbor, 
MI, USA; MMP-3, Human Total MMP-3 Immunoassay, R&D Systems) 
 
Animals 
Six- to seven-week-old female Lewis rats were purchased from Charles 
River Laboratories (Yokohama, Japan) and housed under 12-h light/dark 
cycles at a controlled temperature (23 ± 1 °C), with tap water and standard 
laboratory chow available ad libitum. Rats were allowed to habituate to the 
housing facilities for at least 3 days before compound treatment or mitogen 
stimulation. All experiments were conducted in accordance with the Astellas 
Pharma Inc. guidelines for the care and use of animals and under approved 
protocols of the Institutional Animal Care and Use Committee of Astellas 
Pharma Inc. 
 
Rat acute LPS or Con A-induced cytokine production models 
Female Lewis rats were utilized for in vivo LPS- or Concanavalin A (Con 
A)-stimulated inflammatory cytokine production studies with four and three 
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animals in the vehicle and AS1940477-treated groups, respectively. 
AS1940477 was suspended in 0.5% methyl cellulose and orally administered 
to animals in a volume of 5 mL per kg of body weight. Rats were orally 
administered vehicle or the indicated dose of AS1940477 4 h before LPS or 
Con A (Vector Labs, Burlingame, CA, USA) intravenous injection. LPS and 
Con A were challenged at a dose of 10 µg/animal or 3 mg/animal in each 
study. Animals were anesthetized 1.5 and 2 h after LPS injection or 4 h after 
Con A injection, and blood was collected. TNFα, IL-1β, and IL-6 levels in the 
collected plasma were measured via ELISA 1.5 h, 1.5 h, and 2 h after LPS 
injection, respectively, and IL-2 levels were measured 4 h after Con A 
injection. TNFα was detected using an in-house ELISA system with purified 
hamster anti-mouse/rat TNFα, biotin anti-mouse/rat TNFα (BD Biosciences 
Pharmingen), and recombinant rat TNFα (R&D Systems). IL-1β, IL-6, and 
IL-2 were also detected via a rat IL-1β/IL-1F2 DuoSet kit, rat IL-6 
Quantikine kit (R&D Systems), and rat IL-2 Immunoassay Kit (Biosource 
International), respectively.  
In the study on the long-lasting effects of AS1940477, vehicle or the 
indicated dose of AS1940477 were administered 4 or 20 h after LPS injection, 
and TNFα levels in the collected plasma were measured via ELISA in the 
same way as described above. 
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Results 
 
Selective inhibition of p38 MAPKs activity by AS1940477 
I identified novel p38 MAPK inhibitors by performing a cell-based 
screening in a 96-well format of in-house chemical libraries, including over 
16,000 compounds, to obtain a lead compound that inhibit TNFα production 
in LPS-stimulated human PBMCs, optimization of which yielded AS1940477 
(Fig. 1). AS1940477 potently inhibited p38α kinase activity with an IC50 
value of 11.2 nM (Fig. 2) and showed slightly weaker inhibition of p38β (IC50 
36.5 nM) but did not inhibit 100 representative protein kinases, including 
other p38 isoforms (p38γ, p38δ) and JNK2, at concentrations up to 1 µM 
(Table 1). 
 
Inhibition of the p38 pathway but not JNK or NFκB pathways in THP-1 cells 
by AS1940477 
Given that p38, JNK, and NFκB pathways are closely associated with 
inflammatory responses and the cross-talk between the p38 pathway and 
other signal transduction pathways such as JNK and NFκB, I examined the 
selectivity of AS1940477 in cell-based assay. I first stimulated a human 
monocytic THP-1 cell line with LPS for 30 min and then measured 
phospho-HSP-27, phospho-c-Jun, and total IκBα levels in cell lysates via 
ELISA, as HSP-27 and c-Jun are known to be located downstream of p38 and 
JNK, respectively [15, 16]. IκBα degradation level is also known to reflect the 
activation status of the NFκB pathway [17]. AS1940477 suppressed 
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LPS-induced phosphorylation of HSP-27 with an IC50 value of 4.1 nM (Fig. 3 
A), a value greater than that observed for the p38 kinase inhibitor SB203580 
(360-fold weaker IC50 value, data not shown), while no inhibitory effect was 
observed on either the phosphorylation of c-Jun or IκBα degradation at 
concentrations up to 1 µM (Fig. 3 B, 3 C). The similar selectivity profile was 
confirmed in Western blot analysis (Fig. 3 D). These results indicated that 
AS1940477 has no effect on JNK or NFκB pathways and that its inhibitory 
effect was highly selective for the p38 pathway in the cellular context. 
 
Blockade of cytokine production by AS1940477 in endotoxin-stimulated 
human cells 
I next studied the effects of AS1940477 on cytokine production (TNFα, 
IL-6, IL-1β, and IL-10) in LPS- or PHA-stimulated human cells. LPS and 
PHA were used as activators of monocytes/macrophages and T cells, 
respectively. LPS-induced TNFα production in THP-1 cells and human 
PBMCs was blocked by AS1940477 with IC50 values of 0.6 nM and 0.45 nM, 
respectively, in a concentration-dependent manner (Fig. 4, Table 2). I then 
assessed the effect of AS1940477 on LPS-induced TNFα release in human 
whole blood. The results showed that AS1940477 potently inhibited TNFα 
release from LPS-stimulated whole blood with an IC50 value of 12 nM (Table 
2). In addition to TNFα, LPS-induced IL-1β and IL-6 production was also 
suppressed in human PBMCs at almost the same concentration which 
induced TNFα suppression (IC50 values: 0.55 nM and 3.5 nM, respectively) 
(Table 2). Further, AS1940477 inhibited PHA-induced cytokine production 
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(TNFα, IL-6, and IL-10) in human PBMCs with respective IC50 values of 0.40 
nM, 1.2 nM, and 6.1 nM for each cytokine, whereas PHA-induced IL-2 
production was not inhibited by AS1940477 at concentrations up to 10 µM 
(Table 2). 
 
Effect of AS1940477 on TNFα and IL-1β-induced production of inflammatory 
mediators in healthy human synovial stromal cells 
In addition to its critical role in inflammatory cytokine production, p38 
MAPK is also an important signal transduction molecule activated by 
inflammatory cytokines such as TNFα and IL-1β [18]; therefore, I examined 
whether AS1940477 blocked the TNFα and IL-1β signaling cascades in 
healthy human SSCs. TNFα and IL-1β synergistically stimulated SSCs to 
produce large amounts of IL-6, PGE2, and MMP-3, with expression levels 
peaking at 24 h after stimulation. AS1940477 inhibited the production of 
IL-6, PGE2, and MMP-3 in a concentration-dependent manner (Fig. 5 A-C), 
with IC50 values of 0.64 ± 0.55 nM, 0.76 ± 1.0 nM, and 0.88 ± 0.88 nM, 
respectively. 
 
Inhibitory effect of AS1940477 on cytokine production in a rat model of acute 
inflammation  
I then studied the ability of AS1940477 to suppress acute inflammation in 
vivo by evaluating LPS- and Con A-stimulated cytokine production in rats 
(Fig. 6). In this model, TNFα, IL-1β, and IL-6 plasma levels peaked between 
1.5 and 2 h after LPS treatment. At doses of 0.03 to 1 mg/kg, orally 
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administered AS1940477 significantly decreased the plasma concentrations 
of TNFα, IL-1β, and IL-6 in a dose-dependent manner (Fig. 6 A-C). Of note is 
the fact that AS1940477 exerted a suppressive effect on LPS-induced TNFα 
and IL-6 production at an extremely low dose, with ED50 values of 0.053 
mg/kg against both cytokines. In the Con A-stimulated model, the plasma 
concentration of IL-2 peaked at 5 h after stimulation, and AS1940477 had no 
inhibitory effect on IL-2 production (Fig. 6 D). These results suggest that 
AS1940477 has the ability to regulate inflammatory cytokine production in 
vivo, consistent with in vitro studies. 
I also evaluated the long-lasting inhibitory effect of AS1940477 on 
cytokine production in a rat model of LPS-stimulated production of TNFα. 
AS1940477 was administered 20 h before LPS injection, and plasma TNFα 
levels were measured. AS1940477 significantly suppressed LPS-induced 
TNFα production in a dose-dependent manner (p < 0.01 for each dose vs. 
vehicle), which was comparable with the inhibitory activity of AS1940477 4 h 
before LPS injection (Fig. 7). These findings indicated that the in vivo 
inhibitory effect of AS1940477 on cytokine production lasted for 20 h.  
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Discussion 
 
p38 MAPK plays a key role in chronic inflammation, and its therapeutic 
potential has been extensively studied [19]. Over the past decade, many 
small molecule inhibitors of p38 MAPK have been generated and advanced 
to clinical trials; however, undesirable side effects or low efficacy have led to 
the withdrawal of most compounds after initial clinical trials. For example, 
development of BIRB-796, AMG-548, and VX-745 was discontinued due to 
side effects such as gastrointestinal disorders, elevated liver enzyme levels, 
and central nervous system disorders [20], while VX-702 was withdrawn due 
to insufficient efficacy, with only around 40% of rheumatoid arthritis 
patients achieving an ACR20 response [21]. These adverse effects relate to 
the chemical structure or differing kinase selectivity patterns of these agents 
and are believed to be unrelated to p38α inhibition. As such, the next 
generation of p38 MAPK inhibitors needs to be more selective and potent 
than currently available compounds.  
The current study demonstrated the in vitro and in vivo pharmacological 
profiles of a novel small molecule inhibitor of p38 MAPK, AS1940477. I 
evaluated its selectivity against over 100 kinases, in contrast to previous 
reports of p38 inhibitors which featured selectivity data for only a limited 
number of kinases. AS1940477 showed potent inhibition of p38α and p38β in 
cell-free enzymatic assay and high selectivity for p38α and p38β in a kinase 
assay profiling against 100 representative protein kinases, including c-Jun 
N-terminal kinase and p38γ and p38δ isoforms (Table 1). In contrast, 
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clinically advanced p38 MAPK inhibitors such as BIRB796 and Pamapimod 
inhibit not only p38α but also JNK activity in enzymatic assays [22, 23]. I 
also tested the selectivity of AS1940477 for the intracellular signaling 
pathway in THP-1 cells. When the p38, JNK, and NFκB pathways were 
activated in LPS-stimulated THP-1 cells, AS1940477 selectively inhibited 
only the p38 pathway without affecting the JNK or NFκB pathways (Fig. 3), 
indicating selective inhibition of the p38 pathway by AS1940477 in both 
cell-free and cell-based conditions and therefore low likelihood of off-target 
effects compared with other p38 inhibitors such as BIRB796 and 
Pamapimod. 
As the p38 MAPK signaling pathway is closely associated with the 
production of various pro- and anti-inflammatory cytokines and other 
inflammatory mediators [24, 25], I examined the effects of AS1940477 on the 
production of typical inflammatory cytokines and mediators. The results 
showed that AS1940477 reduced the levels of TNFα, IL-1β, and IL-6 
produced from LPS- or PHA-stimulated human monocytic cells and/or whole 
blood (Table 2). LPS is a principal component of gram-negative bacteria [26], 
and PHA is a lectin found in plants, particularly legumes. LPS and PHA 
activate mainly monocytes/macrophages and T cells, respectively [27], 
suggesting that AS1940477 inhibits both monocyte/macrophage- and T 
cell-dependent inflammatory cytokine production. Interestingly, IL-2 
production in PHA-stimulated PBMCs was not affected by AS1940477 at 
concentrations up to 10 µM (Table 2). Although SB203580 was previously 
reported to inhibit IL-2 production in activated T cells [28, 29], another 
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report showed no change in IL-2 production or proliferation in T cells with 
specific inhibition of p38α by dominant negative p38α [30], findings 
consistent with the results of the present study. These results suggest that 
AS1940477 is highly selective for p38α, possessing an anti-inflammatory 
effect without immunosuppression. In addition, a reduction in TNFα- and 
IL-1β-induced IL-6 (Fig. 5 A), PGE2 (Fig. 5 B) and MMP-3 (Fig. 5 C) 
production was observed in human SSCs, indicating that AS1940477 plays 
an important role in the downstream signaling and production of TNFα and 
IL-1β. IL-6 and PGE2 are representative inflammatory cytokines/mediators 
for inflammation and pain, respectively, while MMP-3 is associated with 
joint destruction. Taken together, these findings suggest that AS1940477 can 
inhibit the production and signaling of proinflammatory cytokines, resulting 
in affecting monocytes, T cells, and synovial cells, which are involved in the 
pathogenesis of rheumatoid arthritis. 
I also used a rat model of acute LPS- and Con A-induced cytokine 
production to examine the anti-inflammatory effect of AS1940477 in vivo. In 
the LPS-treated model, AS1940477 significantly reduced plasma 
concentrations of TNFα and IL-6 at doses below 0.1 mg/kg and also partially 
decreased plasma IL-1β levels at 1 mg/kg (Fig. 6 A-C). The lesser effect on 
IL-1β production compared with TNFα and IL-6 production in this model 
may be attributed to the differential contribution of p38α in the generation of 
cytokines. In contrast, AS1940477 did not significantly affect Con A-induced 
IL-2 production at 1 mg/kg (Fig. 6 D). Although the IL-2 level appeared to be 
slightly reduced at 0.3 to 1 mg/kg, the effect was not statistically significant 
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(p > 0.05). The cytokine selectivity of AS1940477 was consistent with that 
observed in the in vitro assay (Table 2); thus, AS1940477 is believed to be 
specific for p38α in vivo. 
In the present study, I showed that AS1940477 potently inhibited the 
production of various inflammatory cytokines such as TNFα from 
LPS-stimulated THP-1 cells and human PBMCs with IC50 values of 0.6 nM 
and 0.45 nM, respectively (Fig. 4, Table 2). The potency of AS1940477 in 
these mononuclear cells is stronger than those of p38 inhibitors in clinical 
testing such as BIRB796, VX-702, Pamapimod, and PH-797804 (IC50 = 3.4 to 
60 nM) [14, 23, 31]. Further, the activity of AS1940477 in whole blood assay 
was more potent than those of other p38 inhibitors; for example, SCIO-469, 
Pamapimod, and PH-797804 inhibited LPS-induced TNFα production in 
whole blood with IC50 values of 300, 400, and 85 nM, respectively [14, 23, 32], 
which were weaker than that of AS1940477 (IC50 = 12 nM). From the results 
of the in vitro study, I expected AS1940477 to show potent activity in vivo 
and tested this in a rat acute inflammation model, where the compound 
suppressed LPS-induced TNFα production at extremely low doses (ED50 = 
0.052 mg/kg, Fig. 6). In comparison, Pamapimod and PH-797804 have been 
reported to inhibit TNFα production in LPS-treated rats with ED50 values of 
0.3 and 0.07 mg/kg, respectively. To the best of my knowledge, no other 
studies have reported on p38 inhibitors with greater potency in vivo than 
AS1940477.  
Given the good pharmacokinetic profile of AS1940477 with no metabolic 
concerns (data not shown), I examined its long-lasting effect using an in vivo 
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acute inflammation model. When AS1940477 was orally administered to rats 
20 h before LPS injection, its suppressive effect was almost the same as that 
seen when given 4 h before LPS injection. This result suggests that the 
potent anti-inflammatory effect of AS1940477 may last for almost one day 
after a single administration. 
Recently, several second generation p38 inhibitors, including VX-702, 
SCIO-469, and ARRY-797, were tested in clinical trials and were found to be 
ineffective in treating rheumatoid arthritis [20, 33-35]. Despite a temporary 
decrease in the plasma CRP levels in the drug-treated groups, levels 
eventually reverted to those of the placebo group. A p38 inhibitor 
BMS-582949 also showed therapeutic effectiveness against rheumatoid 
arthritis in a Phase IIB study without CRP rebound phenomenon [36]; 
unlike SCIO-469 or VX-702, BMS-582949 potentially blocks not only p38 
kinase activity but also p38 activation [37], which may contribute to its 
continuous anti-inflammatory effect. Thus, the role of p38 MAPK in chronic 
inflammatory disease remains controversial and further clinical data will be 
necessary to resolve this issue. 
In summary, I documented the pharmacological profile of AS1940477, a 
novel p38 MAPK inhibitor, and found it to have potent inhibitory activity for 
p38α and p38β without affecting other protein kinases. AS1940477 also 
inhibited LPS- and PHA-stimulated proinflammatory cytokine production in 
human PBMCs and TNFα/IL-1β-induced liberation of inflammatory 
mediators in SSCs and has potent inhibitory activity in whole blood as well 
as in a rat model of acute inflammation with effects lasting for almost one 
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day. Taken together, these results suggest that AS1940477 may be a 
promising anti-inflammatory agent for use in treating chronic inflammatory 
diseases. 
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  Tables and Figures 
 
Table 1. 
Kinase selectivity of AS1940477 
Kinases IC50a, (nM) IC75a, (nM) 
p38α 11.2 18.4 
p38β 36.5 65.8 
p38γ >1000 >1000 
p38δ >1000 >1000 
JNK2 >1000 >1000 
other 97 kinasesb >1000 >1000 
a IC50 and IC75 values are expressed. 
b Ninety-seven kinases: ABL, ACK, AXL, BMX, BTK, CSK, DDR2, EGFR, EphA2, 
FAK, FES, FGFR1, FGFR3, FLT1, FLT3, FLT4, FMS, FYN, HER2, IGF1R, INSR, IRR, 
ITK, KDR, KIT, LTK, LYNa, MER, MET, MUSK, PDGFRa, PDGFRb, RET, RON, ROS, 
SRC, SYK, TEC, TIE2, TRKA, TYRO3, ZAP70, AKT1, AKT2, AurC, BMPR1A, BRAF, 
CaMK2a, CaMK4, CDK2, CDK3, CHK1, CHK2, CK1a, COT, CRIK, DAPK1, DLK, Erk5, 
GSK3a, GSK3b, IKKa, IKKb, JNK3, MAP2K1, MAP2K2, MAP2K4, MAP2K5, MAP2K7, 
MAP3K1, MAP3K2, MAP3K3, MAP3K4, MAP3K5, MAPKAPK3, MAPKAPK5, MINK, 
MLK1, MLK2, MLK3, MNK1, MNK2, MSK1, NEK2, p70S6K, PAK6, PHKG1, PIM1, 
PKACa, PKD2, RAF1, ROCK1, RSK1, RSK2, SRPK2, TAK1, TTK 
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Table 2. 
In vitro effect of AS1940477 on LPS- or PHA-induced cytokine production 
from human PBMCs and whole blood*. 
Cell type Stimulus/cytokine IC50, (nM) 
Human PBMC LPS/TNFα 0.45 
Human PBMC LPS/IL-1β 0.55 
Human PBMC LPS/IL-6 3.5 
Human PBMC PHA/TNFα 0.40 
Human PBMC PHA/IL-6 1.2 
Human PBMC PHA/IL-10 6.1 
Human PBMC PHA/IL-2 >10,000 
Human WB* LPS/TNFα 12 
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Fig. 1. Structure of AS1940477 
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Fig. 2. Effect of p38α MAPK enzyme inhibition by AS1940477. Human 
p38α kinase activity of AS1940477 was evaluated using Z’-LyteTM kinase 
assay system provided by invitorogen corporation. The presented data are 
average values of duplicate analysis obtained two independent experiments. 
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Fig. 3. Cellular selectivity of AS1940477 for p38 versus JNK and NFκB 
signaling pathways in THP-1 cells. THP-1 cells pre-treated with AS1940477 
for 30 min were stimulated with or without LPS 10 µg/mL for 30 min at 
37 °C. The reaction was stopped by adding cold phosphate-buffered saline, 
and cellular lysates were prepared as described in the Methods section. p38 
activity was measured by assessing phosphorylation of HSP-27, JNK activity 
by assessing phosphorylation of c-Jun, and NFκB activity by assessing 
degradation of IκBa via ELISA (A–C) or Western blot (D). The presented 
data are representative of the results obtained from three independent 
experiments.  
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Fig. 4. Effect of AS1940477 on LPS-induced TNFα production in THP-1 cells. 
THP-1 cells were treated with AS1940477 and LPS 10 µg/mL at the same 
time and incubated for 18 h at 37 °C. The concentration of TNFα in the 
supernatant was determined via ELISA. The presented values are expressed 
as the mean ± S.E.M. of triplicate experiments, and the IC50 value was 
calculated using GraphPad Prism 4.0 software. 
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Fig. 5. Inhibitory effect of AS1940477 on TNFα/IL-1β signaling transduction 
in human synovial stromal cells. Human synovial stromal cells were 
stimulated with TNFα (1 ng/mL) and IL-1β (2 pg/mL) for 24 h after a 30-min 
preincubation in the presence or absence of the indicated concentrations of 
AS1940477. IL-6 (A), PGE2 (B), and MMP-3 (C) levels in the culture media 
were determined by ELISA as described in the Methods. Two representative 
data of three independent experiments are displayed.  
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Fig. 6. Effect on in vivo LPS- and Con A-induced inflammatory cytokine 
production. AS1940477 or vehicle (0.5% methyl cellulose) were administered 
orally to female Lewis rats 4 h before i.v. injection of LPS (10 µg/rat) or Con A 
(3 mg/rat). TNFα, IL-1β, and IL-6 levels were measured in collected plasma 
1.5, 1.5, and 2 h after LPS injection, respectively. IL-2 levels were also 
measured in collected plasma 4 h after Con A injection. The values are 
expressed as mean ± S.E.M. Significant differences between vehicle and 
treated groups: *p < 0.05, **p < 0.01 (one- way ANOVA followed by Dunett's 
multiple range test).  
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Fig. 7. Long-lasting effect of AS1940477 in an in vivo model of LPS-induced 
TNFα production. AS1940477 or vehicle (0.5% methyl cellulose) were 
administered orally to female Lewis rats 4 or 20 h before i.v. injection of LPS 
(10 µg/rat). TNFα levels were measured in collected plasma 1.5 h after LPS 
injection. Values are expressed as mean ± S.E.M. Significant differences 
between vehicle and treated groups: **p < 0.01 (one- way ANOVA followed by 
Dunett's multiple range test) 
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Chapter II 
 
 
Inhibition of c-Rel DNA binding is critical for the anti-inflammatory effects 
of novel PIKfyve inhibitor 
  
41 
 
Summary 
 
Aberrant production of proinflammatory cytokines is linked to many 
autoimmune diseases, and their inhibition by small molecule compounds is 
considered beneficial. Here, I performed phenotypic screening in 
IFNγ/LPS-activated RAW264.7, mouse macrophage cells, and discovered 
AS2677131 and AS2795440 as novel and potent inhibitors of IL-12p40, a 
subunit of IL-23. Interestingly, these compounds exhibited unique 
pharmacological activities in their inhibition of the production of IL-12p40, 
IL-6 and IL-1β but not TNFα in activated macrophages or dendritic cells, and 
expression of IgM-induced MHC class II on B cells. To reveal these 
mechanisms, I synthesized two different activity probes which were 
structurally related to the AS compounds, and identified probe-specific 
binding proteins, including PIKfyve, a Class III PI kinase. The AS 
compounds inhibited PIKfyve activity and mimicked the properties of 
PIKfyve-deficient cells, eventually validating PIKfyve as target molecule. 
Regarding mechanism, AS2677131 regulated DNA binding activity of c-Rel 
on IL-12p40 and IL-1β promoter. As expected, a PIKfyve inhibitor prevented 
the development of arthritis in rats. Taken together, my findings of the novel 
and potent PIKfyve inhibitors AS2677131 and AS2795440 reveal the critical 
role of PIKfyve in proinflammatory cytokine production and B cell activation, 
and may indicate a potential new therapeutic option for treatment of 
inflammatory diseases. 
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Introduction 
 
Aberrant production of proinflammatory cytokines is critical to the 
development and progression of many autoimmune diseases, including 
rheumatoid arthritis, psoriasis, and inflammatory bowel disease [2]. IL-23 is 
an inflammatory cytokine that has recently been proposed to play a 
pathogenic role in development of some autoimmune diseases. IL-23 is 
composed of heterodimeric proteins of unique IL-23p19 and common 
IL-12p40 subunits which is shared with IL-12 [38]. IL-12p40-deficient mice 
do not develop arthritis, skin disease, or intestinal inflammation because of 
impaired production of IL-23 [39, 40]. Therefore, pharmacological inhibition 
of IL-12p40 production has been thought as a potential new therapeutic 
option for the treatment of these diseases. 
IL-12p40 is produced primarily by activated macrophages and DCs, when 
these cells are stimulated by a variety of pathogenic or inflammatory agents. 
In particular, LPS and IFNγ are strong inducers of IL-12p40, and the 
signaling pathway in their induction of IL-12p40 expression has been well 
investigated [41]. Cells stimulated with LPS and IFNγ show activation of 
various intracellular signaling proteins, such as NFκB and interferon 
regulatory factor (IRF), followed by binding of these protein to their response 
site on a target gene promoter, resulting in elevation of IL-12p40 mRNA. The 
mammalian NFκB family proteins consist of five members, c-Rel, p65/RelA, 
RelB, p50/NFκB1, and p52/NFκB2. c-Rel is specifically expressed in 
lymphoid and myeloid cells, and is essential for expression of IL-12p40 in 
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macrophages [42].  
Phosphoinositides play crucial roles in a variety of cellular processes [43], 
and their metabolism is controlled by highly specific kinases and 
phosphatases via reversible phosphorylation at positions 3, 4, and/or 5 of the 
inositol headgroup in PI. PIKfyve, a FYVE finger-containing 
phosphoinositide kinase, is an evolutionarily conserved mammalian lipid 
kinase that acts on PI and PI3P to generate PI5P and PI(3,5)P2, respectively 
[6]. Functional impairment of PIKfyve leads to aberrant endosome 
enlargement and marked cytoplasmic vacuolation, as a consequence of 
impaired normal endosome processing and membrane trafficking [44-47]. 
Since PIKfyve regulates pleiotropic cell functions, a comprehensive 
understanding has yet to be obtained. 
I here report the discovery of two small molecule compounds, AS2677131 
and AS2795440, which exert unique immunoregulatory functions, selective 
cytokine inhibition and B cell activation inhibition. I also identified PIKfyve 
as a direct target molecule of these compounds by a chemical biological 
approach, and further study revealed that inhibition of intracellular PIKfyve 
activity by AS2677131 selectively decreased c-Rel binding to gene promoters 
of IL-12p40 and IL-1β, indicating that AS2677131 regulates cytokine 
production through a PIKfyve-c-Rel pathway. Oral administration of 
AS2677131 suppressed chronic inflammation, as indicated by the inhibition 
of development of adjuvant-induced arthritis in rats. Collectively, my 
findings describe novel and selective PIKfyve inhibitors which show potent 
anti-inflammatory effects, and may indicate that PIKfyve is a potential new 
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therapeutic target for the treatment of various inflammatory diseases. 
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Materials and Methods 
 
Reagents 
AS2677131 
(rel-N-{6'-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-3,3'-bipyridin-5-yl}-3-ethyl-2-
methyl-1H-pyrrolo[3,2-b]pyridine-5-carboxamide), AS2795440 
(N-(1''-isopropyl-6-methyl-1'',2'',3'',6''-tetrahydro-3,3':6',4''-terpyridin-5-yl)-2,
3-dimethyl-1H-pyrrolo[3,2-b]pyridine-5-carboxamide), and AS2559819 
(N,2,3-trimethyl-N-(5-{4-[2-(morpholin-4-yl)ethoxy]phenyl}pyridin-3-yl)-1H-i
ndole-5-carboxamide) were synthesized by Astellas Pharma Inc. (Ibaraki, 
Japan). The general synthetic routes of AS2677131 and AS2795440 were 
previously described [48]. 
 
Cell culture  
A mouse macrophage cell line, RAW264.7, was routinely cultured in 
DMEM/F12 supplemented with 5% FCS (BioWest) and 1% 
penicillin/streptomycin [10,000 units of penicillin per mL, 10,000 µg of 
streptomycin per mL]. Peritoneal macrophages were prepared as previously 
described with minor modification [49]. Mice were injected i.p. with 2 mL of 
3% thioglycolate (Difco) and cells were harvested from the peritoneal cavity 4 
days after by lavage with cold PBS. DCs were obtained by differentiating 
bone marrow with RPMI supplemented with 10% FCS, 1% 
penicillin/streptomycin [10,000 units of penicillin per mL, 10,000 µg of 
streptomycin per mL], 5 ng/mL GM-CSF, and 5 ng/mL IL-4 for 7 d. 
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Peritoneal macrophages and DCs were cultured in RPMI medium 1640 
supplemented with 10% FCS and 1% penicillin/streptomycin [10,000 units of 
penicillin per mL, 10,000 µg of streptomycin per mL]. RAW264.7 cells were 
pre-stimulated with 100 ng/mL of mouse IFNγ (Peprotech) for 7-10 h and 
stimulated with 10 µg/mL LPS (Sigma) in the presence or absence of 
compounds overnight. Peritoneal macrophages were costimulated with 3 
ng/mL of mouse IFNγ and 1 µg/mL of LPS in the presence or absence of 
compounds overnight. DCs were pre-stimulated with 3 ng/mL of mouse IFNγ 
for 7-10 h and stimulated with 1 µg/mL LPS and 10 µg/mL 
muramyldipeptide/MDP (Peptide Institute, Inc.) overnight. 
 
Cytokine mRNA analysis and ELISA  
Total RNA was sequentially extracted from RAW264.7 cells at 0, 0.5, 1, 2, 
and 4 h after stimulation with IFNγ and LPS. cDNA was prepared, labeled, 
and hybridized to the commercial GeneChip according to the manufacturer’s 
standard protocols (Agilent Technologies). Cytokine analysis was performed 
according to the manufacturer’s instructions (Pharmingen, Biosource, or 
R&D Systems). Supernatants and plasma sample were subjected to ELISA 
for IL-12p40, IL-6, and TNFα using a sandwich ELISA system. Following 
antibodies were purchased from Pharmingen: purified rat anti-mouse IL-12 
p40/p70, biotin rat anti-mouse IL-12 (p40/p70), purified rat anti-mouse IL-6, 
biotin rat anti-mouse IL-6, purified hamster anti-mouse/rat TNF, and biotin 
rabbit anti-mouse/rat TNF. The following ELISA standard proteins were 
purchased from Peprotech: recombinant murine IL-12, recombinant murine 
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IL-6, recombinant murine TNF-α, and recombinant rat TNF-α. Rat IL-12p40 
and rat IL-6 were quantified using CytoSet (Biosource) and Duoset (R&D 
Systems), respectively. 
 
Intracellular Ca2+ measurement  
Ramos cells were loaded with 1 µM Fluo-4-AM (Dojinkagaku) for 60 min 
at room temperature in HBSS (20 mM HEPES; pH7.4) in the presence of 
0.01% pluronic acid. Cells were dispensed in 384-well clear-plate (Greiner) in 
the presence of DMSO or compounds. After acquisition of a baseline value, 
the cells were stimulated with anti-IgM, and Ca2+ was measured with a 
FDSS 7000 kinetic plate reader (Hamamatsu Photonics) using a standard 
Fluo-4 480-nm excitation and 530-nm emission filter set. 
 
In vivo antibody production model  
TNP(90)-AECM-Ficoll (Biosearch Technologies) was diluted with saline to 
200 µg/mL, and injected into female Lewis rats (500 µL/head, i.v., n = 5) on 
day 0. Vehicle (0.5% MC) or AS2795440 were orally administrated to rats at 
indicated concentrations from day 0 to day 6. The concentration of anti-TNP 
IgM antibody was measured by ELISA. The anti-TNP IgM was bound to 
plates precoated with TNP-BSA (Biosearch Technologies), and then detected 
by HRP-conjugated rat anti-IgM antibody (American Qualex). 
 
Synthesis of photoreactive affinity capture probe  
Tool compounds High and Low were synthesized in-house and the Linker 
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was kindly provided by Prof. Akito Tanaka, Hyogo University of Health 
Science. The tool compounds and Linker were reacted with 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and 1-hydroxybenztriazole 
in DMF at room temperature. After purification with SepPak plus C18 
(Waters), the acquired amides were used as photoreactive affinity capture 
probes. 
 
Pull down experiments with photoreaction  
RAW264.7 cells were lysed in 0.2% CHAPS lysis buffer (0.2% CHAPS, one 
tablet of cOmplete EDTA-free Protease Inhibitor Cocktail Tablets (Roche) 
per 50 mL of HBS-N (GE Healthcare)). The centrifuged lysates (5 mg/mL) 
were incubated with Dynabeads MyOne Streptavidin C1 (Invitrogen) for 
preclearing. After removal of the beads with a magnetic block, 1 µL of a 
competitor (10 mM), the tool compound High in DMF, or DMF only was 
added to the lysates (100 µL/test) and they were incubated for 30 min at 4 °C. 
Then, 1 µL of the probes (0.1 mM) was added to the solution and they were 
incubated for 2 h at 4 °C. After dilution with 900 µL of 0.2% CHAPS lysis 
buffer, the solutions were exposed to UV light (wave length 302 nm) for 1 min 
at 4 °C. The solutions were then incubated with Dynabeads MyOne 
Streptavidin C1 (50 µL slurry/test) for 30 min at 4 °C. The beads were 
collected with the magnetic block, and washed three times with 0.1% SDS in 
HBS-EP (GE Healthcare) and once with water. 
 
Protein digestion and mass spectrometry  
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Nine microliters of digestion buffer (0.01% SDS and 0.5 mM CaCl2 in 50 
mM ammonium biscarbonate) and 1 µL of trypsin solution (0.5 µg/µL, 
Promega) were added to the collected beads, and they were incubated for 16 
h at 37 °C. After dilution with 100 µL 0.1% formic acid/46% acetonitrile, they 
were applied to the Stage tip purification method [50] with SCX and SDB-XC 
Empore discs (3M). For the SCX stage tip, the applied samples were washed 
with 0.1% formic acid/46% acetonitrile, eluted with 500 mM ammonium 
formate/45% acetonitrile (pH 3.0 by TFA) and diluted 20 times with water. 
For the SDB-XC stage tip, they were washed with 0.1% formic acid/2% 
acetonitrile (LC-A solution), eluted with 0.1% formic acid/90% acetonitrile 
(LC-B solution) and then evaporated. The desalted samples were dissolved 
with LC-A and loaded directly onto a C18 analytical column (3 µm, 0.075 mm 
x 150 mm, Nikkyo Technos). The experiments were performed using an 
Ultimate 3000 liquid chromatography system (Dionex) connected with an 
LTQ Orbitrap XL mass spectrometer (Thermo Fisher) utilizing a 
nano-electrospray ion source. LC separation was performed at a flow rate 
400 nl/min with a linear gradient of 2-45% LC-B over 80 min, followed by an 
additional 5 min at 90% LC-B. Mass spectrometric analysis was performed 
in data-dependent mode to take up to three product ion scans for the three 
highest intensity peaks in each full scan (m/z: 400-1500, set resolution: 
60000), with the lock mass option at m/z 445.1200. Protein identification was 
performed using Mascot software (Version 2.3, Matrix Science Inc.) against a 
protein database based on an NCBI REFSEQ protein sequence 
(ftp://ftp.ncbi.nlm.nih.gov/refseq/M_musculus/mRNA_Prot/mouse.protein.faa
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.gz, built in 2010 Oct; 25163 sequences). Identification results from the 
Mascot software were summarized and integrated with gene annotations 
using an original program developed in-house. Acetylation (protein N-term), 
oxidation [51] and pyro-Glu (N-term Glu and Gln) were set for variable 
modifications. Precursor ion and fragment ion mass tolerances were set to 10 
ppm and 0.8 Da, respectively. Up to three missed trypsin cleavages were 
allowed. Peptide identification criteria was p <0.05, where p was the 
probability that the observed match was a random event. 
 
Immunoprecipitation for PIKfyve enzyme assay  
The lysate of RAW264.7 cells was immunoprecipitated with anti-PIKfyve 
antibody (ProteinTech). Control immunoprecipitates with normal rabbit IgG 
(Cell Signalling Technology) were run in parallel in every experiment. Prior 
to the immunoprecipitations, the cells were lysed in RIPA buffer (Sigma) 
supplemented with protease & phosphatase inhibitor cocktail (Thermo). The 
centrifuged lysates (2 mg/1 mL/test) were incubated with antibodies (5 
µg/test) overnight at 4 °C. Protein G Mag sepharose beads (50 µL slurry/test, 
GE Healthcare) were added to the final 2 h of incubation at 4 °C. 
Immunoprecipitates were washed three times with HBS-EP buffer (GE 
Healthcare) and twice with kinase assay buffer (50 mM Tris pH 7.5, 1 mM 
EGTA, 1.5 mM MgCl2) for PIKfyve enzyme assay.  
 
PIKfyve enzyme assay with MALDI-TOF mass spectrometry 
(MALDI-TOFMS) analysis  
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For PIKfyve enzyme assay, immunoprecipitates were used after washing 
without the elution step. The kinase reaction using endogenous 
PIKfyve-binding beads (20 µL final volume) was carried out for 6 h at 37 °C 
in kinase assay buffer supplemented with 300 µM ATP (Promega), 300 µM 
PI(3)P diC8 (Echelon, P-3008) and the AS compounds (0, 50, and 200 nM). 
The matrix solution for MALDI-TOFMS analysis was prepared with 90 µL of 
norharmane and 10 µL of harmaline (4 mg/mL in acetonitrile/water/TFA = 
50/50/1 for both) [52]. One microliter of the reacted samples were mixed with 
4 µL of the matrix and the mixture was spotted at 1 µL each on three wells of 
a 384-well MALDI-TOFMS plate (AB Sciex). Negative ion mass spectra were 
recorded on a 4800 MALDI-TOF/TOF analyzer (AB Sciex) using the 
manufacturer’s standard parameter setting for reflector mode with a mass 
range of m/z 500-2000 and 4000 laser shots/well. Signal to noise ratio (S/N) of 
m/z 745.2 for the enzymatic reaction product, PI(3,5)P2 diC8, was 
automatically calculated from the obtained spectra. The S/Ns of the product 
at 50 and 200 nM inhibitor concentrations were compared to that at 0 nM (no 
inhibition) to calculate a % inhibition rate of this assay. The % inhibition rate 
was averaged from the three measurements in each sample. 
 
PI3K enzyme assay 
Catalytic activity of PI3Kα was measured by Kinase-Glo Assay. In brief, 
the kinase reactions were performed in 384-well plates (Greiner). Each well 
was loaded with 0.5 µL of test compounds (in 10% DMSO) and 4 µL of 
reaction buffer (2.5 µM ATP, 12.5 mM MnCl2, 50 mM HEPES, pH7.3, 100 
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mM NaCl, 10 mM MgCl2, 2 mM EGTA, 2 mM DTT). The reaction was 
initiated by the addition of 5 µL of enzyme/substrate mix (14 ng/µL of PI3Kα 
and 40 µg/mL of L-alpha-phosphatidylinositol) and terminated by the 
addition of Kinase-Glo buffer (Promega) after incubation for 3 h at 37 °C. The 
plates were read in a plate reader (SPECTRAmax) for luminescence 
detection. PI3Kβ and PI3Kδ kinase activities were evaluated following the 
manufacturer’s instructions, PI3-Kinase HTRFTM Assay Kit (Millipore). 
 
Western blotting  
The samples were resolved by SDS-PAGE and transferred to PVDF 
membranes (BioRad). The membranes were blocked and incubated 
sequentially with the primary then secondary antibodies. The blots were 
developed using the ECL system (GE Healthcare) in accordance with the 
manufacturer’s instructions. The primary antibodies used for this study are 
listed in Table 3. 
 
Microscopy  
RAW264.7 cells were stimulated with IFNγ and LPS in the presence of 
DMSO or compounds (100 nM) as described above. After 2 h, cells were fixed 
with 4% paraformaldehyde phosphate buffer solution (Wako). Images were 
acquired using a phase-contrast microscope (ECLIPSE Ni-E, Nikon) 
equipped with 100x oil objective. NIS-Elements AR software was used for 
image analysis. 
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ChIP Assay 
The ChIP assay was performed with a SimpleChIP® Enzymatic 
Chromatin IP Kit (Cell Signaling Technology). Cells were used for RAW264.7 
cells stimulated with 100 ng/mL IFNγ and 1 µg/mL LPS for 2 h. c-Rel- or 
PU.1-DNA complexes were immunoprecipitated using anti-c-Rel or 
anti-PU.1 antibody (Table 3). Precipitated, purified DNA was used as a 
template for PCR amplification using primers (Table 4). 
 
Promoter-luciferase reporter assay  
For the luciferase reporter assay, I used the promoter fragment (-313/+12) 
of the mouse p40 gene, which contains several essential response site for 
IL-12p40 functional expression, such as ets-2, PU.1, NFκB, C/EBP, and 
interferon-stimulated response element (ISRE) [53, 54]. A fragment of the 
p40 promoter prepared from mouse genomic DNA (Clontech) by a PCR-based 
method was ligated into the XhoI/HindIII cleavage site of a pGL4.10 vector 
(Promega). RAW264.7 cells were transiently co-transfected with reporter 
gene plasmid and phRL-null Renilla plasmid (Promega) using Nucleofector 
(Lonza). Five hours after transfection, the cell culture medium was changed 
to complete medium containing 10% FBS and stimulated with IFNγ (100 
ng/mL) for 16 h, followed by LPS (10 µg/mL) for an additional 6 h. 
Dual-Luciferase Reporter Assays (Promega) were performed according to the 
manufacturer's instructions. Firefly luciferase activity was normalized to 
Renilla activity. Reporter activity is shown as the average of three 
determinations and standard error. 
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siRNA transfection  
c-Rel and scrambled control small interfering RNA (siRNA) were 
purchased from RNAi Co. or Invitrogen (Table 5). Peritoneal macrophages 
were transfected with 20 nM siRNA using LipofectamineTM RNAiMax 
Transfection Reagent (Life Technologies) overnight. Medium was then 
changed to DMEM containing 10% FCS, penicillin/streptomycin-free. After 
48 h, cells were stimulated with 3 ng/mL mouse IFNγ and 1 µg/mL LPS for 8 
h, and IL-12p40 and TNFα concentrations in the supernatants were 
measured by ELISA. 
 
Flow cytometry  
Whole blood from AS2795440 or vehicle-treated rats was diluted ten 
times with RPMI medium and stimulated with anti-IgM (10 µg/mL) 
(Southern Biotechnology) in a 48-well plate. After incubation for 4 h at 37 °C, 
samples were washed with PBS and then stained with PE-conjugated 
anti-rat CD45R antibody (Pharmingen) and FITC-conjugated anti-rat MHC 
class II antibody (eBioscience) for 30 min at room temperature, then 
analyzed using a FACSCaliburTM instrument (Becton Dickinson) with CELL 
Quest software. Whole blood collected from AIA at day 25 was stained with 
allophycocyanin (APC)-conjugated anti-rat CD45RA antibody, 
FITC-conjugated rat CD3, and PE-conjugated anti-rat CD62L (Pharmingen) 
for 30 min at 4 °C and analyzed using a FACSCantoIITM instrument (Becton 
Dickinson) with BD FACSDivaTM software. 
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Arthritis model  
All animals were held under sterile pathogen-free conditions, and animal 
experiments were approved by the Institutional Animal Care and Use 
Committee of Astellas, in accordance with AAALAC guidelines. AIA was 
achieved by immunization of 6-week-old Lewis rats (Charles River 
Laboratory) with complete Freund’s adjuvant as described previously [55]. 
Normal untreated (NT) or vehicle-treated (CT) rats were used as negative or 
positive controls, respectively. After arthritis induction, the left hind paw 
volume was measured on days 1, 11, 15, and 25 by a water displacement 
method using a plethysmometer for rats (MK-550; Muromachi Kikai Co., 
Ltd.). Rats were orally administered AS2795440 (1-10 mg/kg) or vehicle 
(0.5% MC) once per day from day 1 to 24. Vehicle and AS2795440-treated 
groups consisted of 5-10 animals per group. The normal untreated group 
consisted of 2 animals per group. Histologic evaluation of arthritis severity 
was performed on the formalin-fixed left hindlimb joint by Sapporo General 
Pathology Laboratory. The severity of disease in joints was graded on a scale 
of 0-3, according to an in-house scoring system: 0: normal, 1: slight change, 2: 
moderate change,  3 :  severe change ( for detai ls  see Table 6) 
 
Statistics  
Statistical analysis using Student’s t-test (for single comparisons) or 
one-way ANOVA (for multiple comparisons) was performed using Prism 
software (version 4; GraphPad Software, Inc.). Data that satisfied the 
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confidence levels of p < 0.05, 0.01, and 0.001 are noted. Data are presented as 
means ± S.E.M., unless otherwise noted. 
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Results 
 
AS2677131 and AS2795440 inhibited proinflammatory cytokine production 
both in vitro and in vivo. 
I first conducted cell-based phenotypic screening for IL-12p40 production 
inhibitors, optimized chemical structure, and obtained two novel inhibitors, 
AS2677131 and AS2795440. These compounds potently inhibited IL-12p40 
production in IFNγ/LPS-stimulated RAW264.7 cells, a mouse macrophage 
cell line, with IC50 values of 2.4 and 2.0 nM, respectively. AS2559819, an 
inactive compound, induced no change in IL-12p40 production (IC50, > 10 
µM) and was used as a negative control in the following studies (Fig. 8 and 9 
A). To examine the effect on other proinflammatory cytokines, the mRNA 
expression patterns of several representative proinflammatory cytokines 
were analyzed in IFNγ/LPS-stimulated RAW264.7 cells. After stimulation 
with LPS, gene expression of TNFα peaked in less than 1 h in the control 
group, followed by an increase in IL-1β, IL-12p40, and IL-6 expression over 
the following 4 h (Fig. 9 B). In the AS2677131-treated group, the mRNA 
expression of IL-12p40 and IL-1β was strongly suppressed and that of IL-6 
was partially suppressed, while that of TNFα was not (Fig. 9 B). I next 
checked whether this unique cytokine selectivity profile was also shown at 
the protein level. Thioglycolate–induced peritoneal macrophages were 
stimulated with IFNγ and LPS, and bone marrow-derived DCs were 
stimulated in combination with IFNγ, LPS, and muramyldipeptide (MDP). 
The concentrations of proinflammatory cytokines in the supernatant were 
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measured by ELISA. The results showed that AS2677131 and AS2795440 
selectively inhibited the production of IL-12p40 and IL-6 (Fig. 9 C), and also 
inhibited IL-1β in RAW264.7 cells (data not shown). In contrast, these 
compounds had no effect on TNFα protein production. Inactive compound did 
not inhibit the production of any cytokine (IC50 values, >10 µM). 
I next examined the in vivo anti-inflammatory effect of these compounds 
using Toll-like receptor (TLR) ligand-induced inflammation models. To 
simultaneously detect IL-12p40, IL-6, and TNFα levels, I intravenously 
injected Poly(I:C), a TLR3 ligand, to MDP-primed rats, and then measured 
their cytokine plasma concentrations at 2 h after Poly(I:C) injection by 
ELISA. AS2677131 and AS2795440 were orally administered to rats at 1 h 
before Poly(I:C) injection. Both compounds significantly decreased the 
plasma levels of IL-12p40, IL-6, and TNFα in a dose-dependent manner (Fig. 
9 D). Interestingly, TNFα production was abrogated in AS2677131 and 
AS2795440-treated rats, unlike findings in the in vitro study (Fig. 9 D). 
 
B cell function was inhibited by AS2677131 and AS2795440. 
I next investigated the effect of these agents on immune regulatory 
function, particularly in B cells. First, I investigated their effect on 
intracellular Ca2+ signaling in a human B cell line, Ramos cells. Cells 
stimulated with anti-IgM showed an immediate increase in Ca2+ influx. 
AS2677131 or AS2795440 had little or no effect on Ca2+ influx up to 10 µM 
(Fig. 10 A). This result suggests that these compounds do not directly affect 
BCR-mediated Ca2+ signaling. I next examined whether the compounds 
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affect B cell activation state. I evaluated the expression level of cell surface 
MHC class II on CD45R+ B cells in anti-IgM-stimulated whole blood from 
rats treated with AS2795440. The results showed that AS2795440 
significantly reduced MHC class II expression by 43.6%, 54.8%, and 83.1% at 
doses of 1, 3, 10 mg/kg, respectively, compared with the control (CT) group 
(Fig. 10 B). Similar effect was observed when I used AS2677131 (data not 
shown). To evaluate the effect on antibody production in vivo, TNP-Ficoll, a T 
cell-independent antigen, was injected intraperitoneally into rats on day 0 
and the effect on anti-TNP IgM antibody production from day 4 to day 7 was 
examined. AS2795440 was used in this model owing to its better physical 
properties for in vivo examination than those of AS2677131. AS2795440 
significantly decreased serum antibody levels by 9.0%, 42.5%, and 84.4% at 
doses of 1 to 10 mg/kg (Fig 10 C). These results indicate that AS2677131 and 
AS2795440 play an important role in BCR-mediated B cell activation 
without affecting Ca2+ signaling, leading to the inhibition of T 
cell-independent antibody production. 
 
PIKfyve was identified as a target protein of AS2677131 and AS2795440. 
Although these results indicated that AS2677131 and AS2795440 inhibit 
proinflammatory cytokine production and B cell activation, the mechanism 
of this regulation remained unclear. To elucidate the direct target protein of 
these compounds, I used a photoreactive affinity pull down method [56]. I 
prepared two compounds, which were structurally related to the AS 
compounds but with different inhibitory activity for IL-12p40, and had a 
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photoreactive linker (Fig. 11). IC50 values of the high and low activity probes 
for IL-12p40 production are 1.2 nM and > 1,000 nM, respectively. The tool 
compounds and linker were connected by a carbodiimide-mediated 
amidation reaction for use as photoreactive affinity probes. The probes were 
incubated with cell lysate prepared from RAW264.7 cells with or without an 
excess amount of a competitor, the tool compound High. After activation of 
an azide group of the probes by UV light irradiation, formed protein-probe 
complex was isolated using avidin-immobilized beads. The captured proteins 
were digested with trypsin and the generated peptide mixture was analyzed 
by liquid chromatography coupled with tandem mass spectrometry. Overall, 
380 proteins were identified (Table 7), but only three of these, PIKfyve, Blvrb, 
and Nqo2, met my criteria, namely identification with two or more peptides 
on the high activity probe without a competitor, and also was not identified 
with a competitor (Table 8). Nqo2 was captured by both the high and low 
activity probes but PIKfyve and Blvrb were not captured by the low activity 
probe (Table 8). These results suggested that PIKfyve and Blvrb have the 
potential to specifically bind to the high activity probe. To confirm if 
AS2677131 and AS2795440 actually modulate PIKfyve or Blvrb activity, I 
constructed enzyme assays and evaluated their activity against them. 
Regarding PIKfyve, both AS2677131 and AS2795440 inhibited the 
production of PI(3,5)P2 from PI(3)P by more than 90% at 200 nM (Fig. 12 A). 
In contrast, no changes in Blvrb activity were observed until both compounds 
were at 10 µM (data not shown). As expected, a series of compounds with a 
similar structure showed strong correlations of PIKfyve inhibition with 
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IL-12p40 inhibition (Fig. 12 B). Similarly, IL-6 inhibition or B cell activation 
inhibition were confirmed to correlate with PIKfyve inhibitory activity (Fig. 
13). These results suggest that AS2677131 and AS2795440 may regulate 
immune function through PIKfyve, although the contribution of other 
kinases cannot be ruled out. I then checked the selectivity profile of other 
lipid kinases of the PI3K family, but found that no compounds affected the 
enzyme activity of PI3Kα, β, or δ until 10 µM (Table 9). I also confirmed that 
a structurally related compound (Compound X) selectively inhibited the 
enzyme activity of PIKfyve without affecting other 148 serine/threonine or 
tyrosine kinases (Table 10). 
   PIKfyve is a mammalian type III PI kinase which plays an important role 
in the PI3-kinase/Akt pathway. I investigated the effect of AS2677131 or 
AS2795440 on Akt phosphorylation in IFNγ/LPS-stimulated RAW264.7 cells. 
Consistent with a previous study with a kinase-dead mutant [57], inhibition 
of PIKfyve activity by AS2677131 or AS2795440 reduced the amount of 
p-Akt to non-stimulated levels, while the inactive compound showed the 
same level as the IFNγ/LPS-stimulated DMSO control (Fig. 12 C). Given 
that other studies have also reported that PIKfyve dysfunction of 
PIKfyveK1831E mutant or siRNA treatment induces endosome enlargement or 
profound cytoplasmic vacuolation in many cell types [45, 46, 58], I examined 
if my compounds show the same phenotype. When RAW264.7 cells were 
incubated in the presence of DMSO or inactive compound for 2 h, 
cytoplasmic vacuolation was not observed in both cells. In contrast, 
treatment with AS2677131 or AS2795440 greatly changed morphology, with 
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an increase in cell size and the appearance of many small vesicles in the 
cytoplasm (Fig. 12 D). Taken together, these data clearly indicate that 
AS2677131 and AS2795440 are selective PIKfyve inhibitors, and that their 
anti-inflammatory effect and anti-humoral response are caused by the 
inhibition of PIKfyve activity. 
 
A novel PIKfyve inhibitor regulated the expression of IL-12p40 by the 0.3 kb 
upstream promoter region in IFNγ/LPS-stimulated RAW264.7 cells. 
To elucidate the PIKfyve-mediated regulatory mechanism of IL-12p40 
production, I analyzed its intracellular signaling pathway in RAW264.7 cells 
using AS2677131 as a representative compound on the basis that both 
AS2677131 and AS2795440 showed the same in vitro profile. Previous 
studies have shown that both IFNγ- and LPS-induced IRF and NFκB 
activation are necessary for maximum expression of IL-12p40, but it was 
unknown which signal was more strongly linked to PIKfyve. To determine 
which signaling pathway is inhibited by my PIKfyve inhibitor, I investigated 
the difference in the effect on IL-12p40 production between LPS and 
IFNγ/LPS stimulation. Consequently, similar IC50 values were observed in 
the presence or absence of IFNγ stimulation (data not shown), suggesting 
that PIKfyve might contribute to the LPS/TLR4 signal transduction pathway. 
It is generally recognized that LPS-induced activation of NFκB plays a 
crucial role in IL-12p40 expression in macrophages [42], and that the 
phosphorylation state of IκBα reflects the level of activation of the NFκB 
pathway. I detected phosphorylated IκBα with Western blot using specific 
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antibodies. After IFNγ/LPS stimulation, the rate of IκBα phosphorylation 
clearly increased, whereas AS2677131 and inactive compound induced 
almost no change in DMSO control (Fig. 14 A), suggesting that AS2677131 is 
likely to regulate either downstream signaling of IκBα modification or a 
IκBα-independent pathway. I then investigated the promoter activity of 
IL-12p40 by luciferase reporter assay. Stimulation of RAW264.7 cells with 
IFNγ/LPS elevated the transcriptional activity of IL-12p40, but AS2677131 
significantly reduced the promoter activity (*; p < 0.05 and **; p < 0.01, 
respectively) in a concentration-dependent manner (Fig. 14 B). In contrast, 
the inactive compound had no effect. These data were consistent with the 
results of Fig. 9 B, in which AS2677131 regulated the expression of IL-12p40 
at the transcriptional level. I next examined whether AS2677131 affects the 
nuclear translocation of transcription factors such as p65, p50, c-Rel, PU.1, 
and IRF-8, which have the potential to bind to the ~0.3 kb promoter of 
IL-12p40. RAW264.7 cells were stimulated with IFNγ/LPS in the presence or 
absence of DMSO or compound, and nuclear extract was isolated and 
immunoblotted with the specific antibodies for indicated transcription 
factors or internal control gene, PARP. The amount of nuclear translocation 
of c-Rel, p65, and p50 was significantly increased by treatment with 
IFNγ/LPS in DMSO control cells, while there were little change in PU.1, 
IRF-8, or PARP (Fig. 14 C). Further, AS2677131-treated cells also showed a 
closely similar band pattern between the presence and absence of IFNγ/LPS 
stimulation, indicating that AS2677131 did not influence nuclear 
translocation of the indicated transcription factors. Taken together, these 
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data suggest that AS2677131 might regulate intranuclear but not cytosolic 
events, such as the binding of transcriptional factors to IL-12p40 promoter 
after its nuclear translocation. 
 
A PIKfyve inhibitor selectively blocked IFNγ/LPS-induced c-Rel binding 
activity on IL-12p40 and IL-1β promoter. 
To next determine whether AS2677131 regulates the binding activity of 
transcription factors to IL-12p40 promoter, I focused on c-Rel among the 
transcription factors described above on the basis that deletion of c-Rel in 
macrophages selectively reduced IL-12p40 production whereas TNFα was 
unaffected [42], a similar pattern to those of my compounds. Two 
c-Rel-specific siRNAs were synthesized, and confirmed to suppress the 
expression of mRNA and protein of c-Rel (Fig. 15 A). Consistent with 
previous reports, specific knockdown of c-Rel by targeted siRNA in 
RAW264.7 cells canceled IFNγ/LPS-induced upregulation of IL-12p40, 
whereas no difference was seen in the expression of TNFα (Fig. 15 A). I then 
determined whether AS2677131 affected binding activity of c-Rel to 
IL-12p40 promoter in RAW264.7 cells. Cells were stimulated with IFNγ/LPS 
in the presence or absence of AS2677131 or inactive compound and 
incubated for 2 h, following which crosslinking by formaldehyde and 
DNA-protein interaction was detected by ChIP analysis. As expected, 
AS2677131 decreased the amount of c-Rel on the IL-12p40 promoter, 
whereas inactive compound had no effect, suggesting that inhibition of the 
binding activity of c-Rel by AS2677131 is depend on PIKfyve (Fig. 15 C). 
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Further, I examined whether AS2677131 inhibited the binding of other 
transcriptional factors to IL-12p40 promoter. PU.1 has its responsive site 
near the c-Rel binding site on IL-12p40 promoter (Fig. 15 B), but AS2677131 
did not affect the binding activity of PU.1 (Fig. 15 C), indicating that 
AS2677131 selectively inhibited the binding activity of c-Rel. Because c-Rel 
also binds to IL-1β promoter and is necessary for its transcriptional activity, 
I examined the effect on the binding activity of c-Rel on the IL-1β promoter 
as well as on IL-12p40 in RAW264.7 cells. As expected, AS2677131 inhibited 
the binding activity of c-Rel in a concentration-dependent manner whereas 
the inactive compound did not (Fig. 15 D). These results demonstrate that 
my PIKfyve inhibitor AS2677131 regulates the binding activity of c-Rel to 
the response site, and thereby inhibits the expression of c-Rel-regulated 
genes such as IL-12p40 and IL-1β. 
 
A PIKfyve inhibitor prevented the development of experimental arthritis. 
Based on the results of in vitro study, I next examined the effect of my 
PIKfyve inhibitor on the development of experimental arthritis in rats. 
Adjuvant-induced arthritis (AIA) is the most frequently used chronic 
inflammation model, and is considered to be caused by the hyperproduction 
of various inflammatory cytokines, such as TNFα and IL-1, and by 
lymphocyte activation [59]. AS2795440 was used for this assay for the same 
reason that AS2795440 had better physical properties than AS2677131. 
Treatment with AS2795440 significantly reduced paw swelling at 3 and 10 
mg/kg doses (34.3%, 78.3% decrease for 3, 10 mg/kg versus control), and also 
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induced the recovery of body weight loss at the 10 mg/kg dose (Fig. 16, A and 
B). In addition, AS2795440 inhibited joint inflammation and bone loss, and 
reduced clinical scores (bone destruction, cartilage destruction, synovial 
thickening, and inflammatory cell infiltration) (Fig. 16 C). To further 
determine the effect of AS2795440 on B cell response, the expression of a cell 
surface CD62L in CD3-CD45RA+ B cells was analyzed from whole blood on 
day 25. CD62L expression was downregulated in accordance with the 
development of AIA and the percentage of CD62Llow cells was measured as a 
B cell activation marker. AIA rats showed an increased rate of CD62Llow B 
cells (46.9%) in whole blood compared with normal (11.1%), whereas 
AS2795440 significantly decreased the rate of CD62Llow B cells in a 
dose-dependent manner (Fig. 16, D and E), which was consistent with the 
data in Fig. 10. Thus, my findings demonstrated that AS2795440, a novel 
PIKfyve inhibitor, prevented the development of AIA, in which inflammation 
and B cell activation were suppressed.  
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Discussion 
 
In this study, I found that AS2677131 and AS2795440, novel small 
molecule inhibitors of proinflammatory cytokine upregulation, including 
IL-12p40, IL-6, IL-1β but not TNFα, demonstrated anti-inflammatory effects 
both in vitro and in vivo. I also found that the compounds inhibited 
BCR-mediated B cell activation and antibody production in vivo. Analysis of 
the inhibitory mechanism of the compounds revealed that PIKfyve, a 
mammalian type III PI kinase, is a target protein of AS2677131 and 
AS2795440. In addition, the compounds selectively regulated the binding 
activity of c-Rel to IL-12p40 and IL-1β promoter in IFNγ/LPS-stimulated 
RAW264.7 cells. With regard to therapeutic effect, I found that AS2795440 
significantly prevented the development of AIA in rats. 
AS2677131 and AS2795440 were discovered by phenotypic screening 
using IFNγ/LPS-activated RAW264.7 cells as IL-12p40 production inhibitors 
without inhibitory effect on TNFα production. The mechanism of how these 
compounds regulate IL-12p40 production and other immune functions was 
therefore initially unknown. I synthesized two photoreactive 
linker-conjugated probes with different activity, and incubated the probes 
with cell lysate collected from RAW264.7 cells. As a result, three binding 
proteins, PIKfyve, Blvrb, and Nqo2 were identified. Among of these proteins, 
the enzyme activity of only PIKfyve was inhibited by AS2677131 and 
AS2795440. I further examined whether these compounds showed typical 
cellular phenotypes observed under the loss of PIKfyve activity, such as 
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downregulation of phosphorylation on Akt Ser473 and a vacuolated cellular 
phenotype [57, 58]. As expected, the compounds induced these characteristic 
phenotypes (Fig. 12 C and D). In order to exclude the possibility of the 
contribution of other kinases, the effects of AS compounds on other lipid 
kinases, serine/threonine or tyrosine kinases were investigated, but the 
results showed no effect on any other protein kinases (Table 9 and 10). These 
data support the idea that my compounds are extremely selective inhibitors 
for PIKfyve. The previously reported PIKfyve inhibitors YM201636 and 
Apilimod have demonstrated selectivity profiles for a limited number of 
kinase proteins [45, 60], albeit based on much less data than my present 
extensive data, suggesting the possibility that my compounds are more 
selective for PIKfyve than YM201636 and Apilimod. I therefore consider that 
AS2677131 and AS2795440 are novel selective inhibitors of PIKfyve. 
Interestingly, my findings do prove a novel immune regulatory function of 
PIKfyve. PIKfyve is a member of an evolutionarily conserved gene family of 
PI(3,5)P2-synthesizing enzymes from mice to humans. This gene was 
originally cloned as a GLUT4 transporter from a mouse F442A adipocyte 
library through screening for transcripts. In mammalian cells, the most 
prominent cellular phenotype under the loss of PI(3,5)P2-synthesizing 
activity of PIKfyve is aberrant endomembrane swelling and vacuolation, 
which are progressively exacerbated in a dose- and treatment 
time-dependent manner of PIKfyve inhibitors [44-47]. PIKfyve has therefore 
been extensively studied, mainly in endosomal membrane systems and in 
insulin signaling [57, 61]. Recently, PIKfyve was identified as a target 
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molecule of Apilimod, an IL-12/23 specific production inhibitor, 
demonstrating that PIKfyve is associated with TLR-induced IL-12p40 
production [60]. However, it remains unclear how PIKfyve regulates 
IL-12p40 production and whether PIKfyve contributes to other immune 
functions. Here, I found that a number of characteristic immune functions 
are regulated through a PIKfyve-dependent pathway. First, PIKfyve was 
found to be involved in the production of proinflammatory cytokines, 
including IL-12p40 and IL-6 in IFNγ/LPS-stimulated macrophages and DCs, 
and in Poly(I:C)-stimulated rats (Fig. 9), because the inhibitory activity on 
PIKfyve was closely correlated with that on IL-12p40 or IL-6 production (Fig. 
12 B and 13 A). As in the case of IL-12p40 and IL-6, the production of IL-1β 
mRNA and protein in RAW264.7 cells was inhibited by AS2677131 (Fig. 9 B 
and data not shown). In contrast, TNFα production was differently regulated 
between in vitro and in vivo conditions. My PIKfyve inhibitors had no effect 
on in vitro TNFα production from various types of cells, but decreased the 
level of plasma TNFα in a dose-dependent manner in rats injected with 
MDP/Poly(I:C) (Fig. 9). This may partially depend on the differences in 
stimulus type or cell source. Elucidating the contribution of PIKfyve in TNFα 
production will require more detailed analysis. Collectively, my data suggest 
that PIKfyve positively regulates a particular kind of proinflammatory 
cytokine production in activated-immune cells in vitro (IL-12p40, IL-6, and 
IL-1β) and/or in vivo (IL-12p40, IL-6, and TNFα). Second, PIKfyve was found 
to play a critical role in humoral immune response, because AS2795440 
dose-dependently suppressed the expression level of B cell activation marker 
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induced by anti-IgM (Fig. 10 B). This effect was confirmed by several 
PIKfyve inhibitors with different activity, which showed the close correlation 
between the inhibitory activity on B cell activation and that on PIKfyve (Fig. 
13). Further examination of the effect on B cell function in vivo demonstrated 
that PIKfyve is involved in TNP-Ficoll-induced antibody responses (Fig. 10 
C). Consistent with these results, AS2795440 dose-dependently decreased 
the number of activated-B cells in the blood in an experimental arthritis 
model (Fig. 16, D and E). These data thus strongly suggest that PIKfyve is 
involved in BCR downstream signaling and plays a crucial role in humoral 
immune response both in vitro and in vivo. My findings also support many 
previous reports that the PI3K signaling pathway is important for B cell 
response to antigen [62, 63]. I therefore consider that the preventive effect of 
AS2795440 on the development of AIA is attributable to its 
anti-inflammatory activity via PIKfyve inhibition. 
   Maximum expression of IL-12p40 in macrophages is generally recognized 
to require the activation of both the LPS-NFκB and IFNγ-IRF pathways. 
LPS and IFNγ-activated cells induce nuclear translocation of transcription 
factors, such as p65, p50, c-Rel, IRF8, and PU.1, and subsequent coordinated 
protein binding on the promoter, resulting in gene expression of IL-12p40 
[41]. To elucidate the regulatory mechanism of IL-12p40 production by 
PIKfyve inhibition, intracellular signal transduction was analyzed in IFNγ 
and LPS-stimulated RAW264.7 cells, particularly with regard to the effects 
of AS2677131 on the phosphorylation and degradation status of IκBα, 
promoter activity, nuclear translocation of transcriptional factors, and their 
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promoter-binding activity. The results showed that AS2677131 specifically 
inhibited c-Rel binding activity but not PU.1 to IL-12p40 promoter in 
macrophages (Fig. 15 C). Similarly, AS2677131 exhibited the dose-dependent 
inhibition of c-Rel binding to the IL-1β promoter (Fig. 15 D). These results 
are consistent with previous reports that c-Rel plays a crucial role in the 
regulation of expression of many cytokines, such as IL-12p40 and IL-1β [64, 
65]. I cannot rule out the possibility that other mechanisms contributed to 
IL-12p40 transcription, because the binding activity of other transcription 
factors described above apart from c-Rel and PU.1 on IL-12p40 promoter has 
not been investigated. Given that some studies indicate that TLR 
ligand-induced IL-6 production in macrophages or DCs is necessary for p50 
[42, 66, 67], my PIKfyve inhibitors might affect the DNA binding activity of 
p50 as well as c-Rel. On the other hand, the question whether PIKfyve 
regulates c-Rel DNA binding ability directly remains to be determined. Zhou 
D and others reported that PI3K activation is essential for TLR-induced 
nucleosome remodeling of IL-12p40 promoter [68], and that PIKfyve may be 
involved in the function of ATP-dependent remodeling complex. A second 
possibility is that PIKfyve phosphorylates c-Rel and regulates its 
transactivating activity, because c-Rel phosphorylation is necessary for 
binding to the target gene promoter [69]. Further studies are needed to 
determine the mechanism by which c-Rel DNA binding ability is regulated. 
In contrast, although the regulatory mechanism of B cell is not still 
confirmed, many studies have indicated that activation of the PI3K pathway 
is necessary for B cell activation [70], and that c-Rel is required for the 
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humoral immune response and protection from apoptosis of B cells [71]. 
c-Rel-deficient mice are resistant to the development of arthritis, in which 
antigen-induced antibody production is impaired [72]. In agreement with 
these data, I demonstrated here that PIKfyve inhibition prevented the 
development of AIA, and that this inhibition involved the suppression of B 
cell activation (Fig. 16, D and E). 
In conclusion, my finding of the novel, highly selective, and orally 
available PIKfyve inhibitors AS2677131 and AS2795440 has provided 
evidence that PIKfyve plays a crucial role in inflammatory cytokine 
production and B cell activation. Further, I revealed that AS compounds 
inhibited c-Rel DNA binding activity through PIKfyve inhibition. These data 
suggest that the blockade of PIKfyve might be a potential therapeutic 
approach in the treatment of inflammatory diseases. 
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Tables and Figures 
 
Table 3.  
List of antibodies 
Antibody Supplier Catalog No. Lot Use 
Akt CST 9272 22 WB 
p-Akt (Ser473) CST 4060 5 WB 
IκBα CST 4812 6 WB 
p-IκBα (Ser32) CST 2859 7 WB 
NFκB p65 SantaCruz sc-372 J2209 WB 
NFκB p50 Abcam ab7971 813867 WB 
c-Rel SantaCruz sc-71 J0609 WB 
c-Rel SantaCruz sc-71X E2510 ChIP 
PU.1 CST 2258 10 WB, ChIP 
IRF-8 SantaCruz sc-13043 A1806 WB 
PARP CST 9542 10 WB 
Normal Rabbit IgG CST 2729 5 EA, ChIP 
PIP5K3 Protein Tech 13361-1-AP 1 EA 
 
CST, Cell Signaling Technology; WB, Western Blot; ChIP, Chromatin 
Immunoprecipitation; EA, Enzyme Assay.  
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Table 4.  
Primers used for RT-PCR or ChIP analysis. 
Gene symbol Forward primer Reverse primer 
Rel 5’-ACATCACCCACCAGCCATAC-3’ 5’-AGTCACTGGTGGCCAGCTT-3’ 
Actb 5’-GGTCATCACTATTGGCAACGA-3’ 5’-GAAGGAAGGCTGGAAAAGAGC-3’ 
Il12b 5’-ACATCACCCACCAGCCATAC-3’ 5’-TGAAAACTAGTGTCAAAACATTCTGG-3’ 
Il1b 5’-TTGCCGCCTCTATTCACCTT-3’ 5’- TCTGGGTGTGCATCTACGTGCC -3’ 
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Table 5.  
siRNA sequences used for c-Rel 
Accession Gene name siRNA name Sense (upper), Antisense (lower) 
- Negative siNC 
CGGCUGCAAUCGAUUGAUAGC 
UAUCAAUCGAUUGCAGCCGAA 
NM_009044 c-Rel sic-Rel_1 
AUAGCAUGUUGACAUCAGAGAUACU 
AGUAUCUCUGAUGUCAACAUGCUAU 
NM_009044 c-Rel sic-Rel_2 
AAGAUUGAUGCUCACAAGUCUUGGG 
CCCAAGACUUGUGAGCAUCAAUCUU 
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Table 6.  
Scoring criteria of each evaluation index in AIA joint. 
Evaluation index Scoring criteria 
Bone destruction 
0:  normal 
1:  localized bone destruction in a single site 
2:  bone destruction in multiple sites, but bone structure is kept 
3:  bone destruction over a wide area, and bone structure is lost 
Cartilage destruction 
0:  normal 
1:  localized small erosion 
2:  erosion over a wide area 
3:  almost all cartilage destroyed or lost 
Synovial thickening 
0:  normal 
1:  localized slight  
2:  localized moderate outgrowth or slight outgrowth over a wide 
sphere 
3:  severe outgrowth or moderate outgrowth over a wide area 
Inflammatory cell 
infiltration 
0:  normal 
1:  slight local inflammatory cell infiltration 
2:  moderate inflammatory cell infiltration over a wide area 
3:  severe inflammatory cell infiltration over a wide area 
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Table 8  
Selected list of captured proteins from photoreactive experiments using two 
types of probes with or without competitor conditions.  
Probe 
Competition 
with High 
Number of identified peptides 
PIKfyve Blvrb Nqo2 
High + Linker - 11 3 7 
High + Linker + 0 0 0 
Low + Linker - 0 0 3 
Low + Linker + 0 0 0 
 
Two probes possessing differential activity (High, 1.2 nM; Low, > 1000 nM) 
were used for assay. 
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Table 9.  
Inhibitory activity on PI3K superfamily enzymes (IC50, µM) 
Compound PI3Kα PI3Kβ PI3Kδ 
AS2677131 >10 >10 >10 
AS2795440 >10 >10 >10 
Inactive >10 >10 >10 
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Table 10.  
Kinase selectivity profile of Compound X against 148 kinases. 
Compound X (1 µM) 
Kinase % Inhibition Kinase % Inhibition Kinase % Inhibition 
ABL 7.8 FGR -2.8 LYNa 1.4 
ACK 1.2 FLT1 1.3 MER 0.7 
BLK 12.7 FLT3 7.6 MET -1.4 
BMX 1.4 FMS 1.4 MUSK -6.3 
BTK 10.8 FRK 0.2 PDGFRa 5.5 
CSK 0.2 FYN 15.2 PYK2 -0.7 
CTK 8.6 HCK 14.0 RET -4.1 
EGFR -0.2 HER2 2.6 ROS 0.8 
EPHA1 -0.6 IGF1R -0.1 SRC 0.6 
EPHA2 -4.7 INSR 5.4 SRM -1.6 
EPHA5 -2.6 IRR -0.3 TEC 3.5 
EPHB1 -11.5 ITK 0.6 TIE2 -1.8 
EPHB4 -2.0 KDR 2.4 TNK1 -1.9 
FAK -0.5 KIT -2.5 TRKA 0.7 
FER -2.8 LCK 5.8 TXK 1.6 
FGFR1 7.6 LTK 0.1 TYK2 -1.7 
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Table 10.  
Kinase selectivity profile of Compound X against 148 kinases. 
Compound X (1 µM) 
Kinase % Inhibition Kinase % Inhibition Kinase % Inhibition 
TYRO3 -6.0 CHK1 -23.5 IKKa 0.7 
YES 3.2 CK1g1 -0.2 IKKb 4.6 
ZAP70 -6.4 CK1e 9.4 IKKe -4.8 
AKT1 0.9 CK2a1/b 0.3 IRAK1 11.6 
AKT2 1.5 CLK1 0.1 IRAK4 -6.8 
AMPKa1/b1/g1 4.2 COT 13.4 JNK1 3.3 
AurC -4.9 CRIK -5.4 JNK2 1.7 
BMPR1A 0.8 DAPK1 -3.6 JNK3 -3.6 
BRAF 1.4 DCAMKL2 -4.1 MAP2K1 14.7 
CaMK1a 1.7 DLK 5.9 MAP2K2 7.0 
CaMK2a -2.8 DYRK1A -14.5 MAP2K3 6.1 
CaMK4 0.5 EEF2K 1.3 MAP2K4 -3.4 
CDC2 4.8 Erk5 14.8 MAP2K5 -6.2 
CDC7 -5.9 GSK3a -2.1 MAP2K7 -5.3 
CDK2/CycA2 0.4 GSK3b 6.8 MAP3K1 -0.7 
CDK3 5.2 HGK 9.5 MAP3K2 1.9 
CGK2 4.0 HIPK1 4.3 MAP3K3 2.2 
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Table 10.  
Kinase selectivity profile of Compound X against 148 kinases. 
Compound X (1 µM) 
Kinase % Inhibition Kinase % Inhibition Kinase % Inhibition 
MAP3K4 3.9 p70S6K -1.5 PKR 4.9 
MAP3K5 -0.5 PAK1 -28.1 PLK1 6.4 
MAP4K2 0.5 PAK6 -62.2 PRKX 0.5 
MAPKAPK2 5.5 PASK -0.1 RAF1 -1.2 
MARK1 12.8 PBK -2.1 ROCK1 0.2 
MELK 8.8 PDHK2 -1.1 RSK1 7.0 
MINK -0.4 PEK 18.9 RSK2 14.6 
MLK1 4.3 PGK -1.3 SGK 5.1 
MNK1 5.9 PIM1 18.5 SLK -1.3 
MRCKa -1.6 PKACa 20.1 TAK1-TAB1 -10.6 
MST1 -2.1 PKCa 4.3 TAOK2 -2.1 
NDR1 -0.4 PKCb1 3.5 TSSK1 -1.9 
NEK2 -1.6 PKCg -1.3 TTK 4.4 
NuaK1 -17.7 PKCd 3.9 WEE1 -1.4 
p38b -5.3 PKCq 2.6 WNK1 -1.2 
p38g -7.3 PKD2 16.0 PIKfyve 95.9 (0.2 µM) 
p38d -1.4 PKN1 -4.7 PIKfyve 48.7 (0.05 µM) 
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Fig. 8. Chemical structures and pharmacological activity of AS2677131, 
AS2795440, and AS2559819. Two active compounds, AS2677131 and 
AS2795440, and an inactive compound, AS2559819. Inhibitory activity of AS 
compounds on IL-12p40 production in IFNγ/LPS-stimulated RAW264.7 cells 
is shown. 
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Fig. 9. AS2677131 and AS2795440 inhibit proinflammatory cytokine 
production. (A) Inhibitory activity of the AS compounds on IL-12p40 
production in IFNγ/LPS-stimulated RAW264.7 cells. Cells were 
prestimulated with IFNγ, followed by addition of compounds and stimulation 
with LPS. IL-12p40 levels were measured by ELISA. Data are presented as 
percentage of DMSO-treated control cells (100%). A representative of three 
experiments is shown. (B) Kinetics of cytokine mRNA levels in 
IFNγ/LPS-stimulated RAW264.7 cells treated with AS2677131 (unfilled) or 
DMSO (filled). Data are normalized relative to β-actin. (C) Effect of the AS 
compounds on the production of IL-12p40, IL-6, and TNFα in activated 
macrophages (Mfg) or DCs (DC). Macrophages were stimulated with 
IFNγ/LPS. DCs were stimulated with IFNγ/LPS/MDP. Cytokine levels were 
determined by ELISA. Data are presented as a percentage of DMSO-treated 
control cells (100%). A representative of three experiments is shown. (D) 
Inhibitory effect of the AS compounds on the production of IL-12p40, IL-6, 
and TNFα in TLR ligand-injected rats. AS2677131 (1, 3, 10, 30 mg/kg), 
AS2795440 (0.3, 1, 3, 10 mg/kg), or vehicle were orally administered to rats 
(n = 4/group) 1 h before i.v. injection of Poly(I:C) (1 mg/rat) and MDP (20 
µg/rat). Cytokine levels were measured by ELISA in collected plasma 2 h 
after injection. Values are expressed as mean ± S.E.M. Significant 
differences between the vehicle and treated groups: *: p < 0.05, **: p < 0.01, 
***: p < 0.001 (Dunnet multiple comparison test). 
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Fig. 9. 
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Fig. 10. AS2677131 and AS27795440 inhibit B cell activation and antibody 
production. (A) BCR-mediated calcium mobilization in anti-IgM-stimulated 
Ramos cells with the AS compounds or DMSO. Following baseline 
acquisition, Ca2+ influx (Max-Min) was calculated. Data are presented as 
percent of control (DMSO-treated cells). A representative of three 
experiments is shown. (B) Expression levels of MHC class II in CD45R+ B 
cells in anti-IgM-stimulated whole blood from rats treated with AS2795440 
or vehicle. Whole blood was collected 2 h after treatment with AS2795440 
(1-10 mg/kg, p.o.) or 0.5% methyl cellulose (MC). 0.5% MC-treated group was 
used as a control (CT). Mean ± S.E.M.; n = 3. (C) Plasma levels of anti-TNP 
IgM antibody in TNP-Ficoll-immunized rats with AS2795440 (1-10 mg/kg, 
p.o., u.i.d.) or 0.5% MC (CT). Data are presented as AUC from day 4 to day 7 
(day 4-7) values. Mean ± S.E.M.; n = 5. Significant differences between 
control and treated groups: *: p < 0.05, **: p < 0.01, ***: p < 0.001 (Dunnet 
multiple comparison test). 
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Fig. 11. Chemical structures and pharmacological activity of probes or linker. 
Structures of two different activity probes, High and Low, that are 
structurally related to AS compounds, or linker. Inhibitory activity of High 
and Low for IL-12p40 production in IFNγ/LPS-stimulated RAW264.7 cells 
are shown.  
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Fig. 12. AS2677131 and AS2795440 are novel PIKfyve inhibitors. (A) 
Inhibitory activity of three AS compounds for the immunoprecipitated 
PIKfyve from RAW264.7 cell lysate. Activity was shown as the percent ratio 
of the control. (B) Correlation between PIKfyve inhibition and IL-12p40 
production inhibition for 12 compounds, namely AS2677131, AS2795440, 
inactive, and nine other structural analogs (A-I). Percentage of inhibition on 
PIKfyve activity at 200 nM and inhibitory activity on IL-12p40 production 
(IC50 values in RAW264.7 cells) were plotted. Inactive (p40; IC50 >10 µM) is 
indicated as 0% at 10 µM. (C) Western blotting for p-Akt and total-Akt in 
RAW264.7 cells treated with the AS compounds or DMSO. Cells pretreated 
with IFNγ (100 µg/mL) were treated with AS compounds or DMSO with LPS 
(10 µg/mL) for 2 h. Inhibitor concentrations were as follows: AS2677131, 
AS2795440 (100 nM), and inactive (1 µM). (D) Phase-contrast images of 
RAW264.7 cells treated with the AS compounds or DMSO. Inhibitor 
concentrations were as follows: AS2677131, AS2795440 (100 nM), and 
inactive (1 µM). Scale bars: 10 µm. 
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Fig. 12. 
  
96 
 
 
 
 
 
 
 
 
Fig. 13. Correlation between inhibition of PIKfyve activity and IL-6 
production or MHC class II expression. Percentage of inhibition on PIKfyve 
activity at 200 nM (A) and inhibitory activity on IL-12p40 production (IC50 
values in RAW264.7 cells) (B) by 12 compounds. Test compounds: AS2677131, 
AS2795440, inactive, and nine other structural analogs (A-I). Inactive (p40; 
IC50 >10 µM) was indicated as 0% at 10 µM. 
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Fig. 14. AS2677131 regulates IL-12p40 expression without affecting IκBα 
phosphorylation or nuclear translocation. (A) Western blotting for p-IκBα 
and total- IκBα in RAW264.7 cells treated with the AS compounds or DMSO. 
Cells pretreated with IFNγ (100 µg/mL) were restimulated with LPS (10 
µg/mL) for 0.5 h in the presence of AS2677131 (100 nM), inactive (1 µM), or 
DMSO. (B) Transient transfection assay of luciferase reporters containing 
fragments of IL-12p40 promoter (~0.3 kb). IFNγ-primed RAW264.7 cells 
were stimulated with LPS in the presence of AS2677131 (10, 100 nM), 
inactive (100 nM), or DMSO. Luciferase activity was measured 6 h after 
stimulation. Relative promoter activity was calculated by normalizing 
luciferase activity against Renilla activity. Values are expressed as mean ± 
S.E.M. Significant differences are shown as *: p < 0.05, **: p < 0.01 (Dunnet 
multiple comparison test, vs IFNγ/LPS-stimulated DMSO control) (C) 
Western blotting for six proteins in RAW264.7 cells treated with AS2677131 
(100 nM) or DMSO. Cells were stimulated with IFNγ and LPS as described 
above for 1 h and then nuclear fraction was isolated, and immunoblotted 
with anti-p65, p50, c-Rel, PU.1, IRF-8, and PARP. 
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Fig. 14.  
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Fig. 15. AS2677131 selectively inhibits DNA-binding affinity of c-Rel to 
IL-12p40 and IL-1β promoter. (A) Effect of c-Rel knockdown on IL-12p40 and 
TNFα production in IFNγ/LPS-stimulated RAW264.7 cells. Cells were 
transfected with siRNAs (sic-Rel) or scrambled siRNA (siNC) for 48 h, and 
the expression levels of c-Rel were detected by real-time PCR or Western 
blotting. After further incubation with IFNγ (100 ng/mL) and LPS (10 
µg/mL), cytokines in supernatants were measured by ELISA. Mean ± S.E.M. 
(B) Schematic representation of endogenous mouse IL-12p40 promoter and 
the annealing positions of primers for quantification of ChIP assay. (C) ChIP 
assay of c-Rel and PU.1 to endogenous IL-12p40 promoter in 
IFNγ/LPS-stimulated RAW264.7 cells treated with the AS2677131 (100 nM), 
inactive (100 nM), or DMSO. Quantification of DNA bound to c-Rel or PU.1 
was performed by real-time PCR (% input mean ± SD. n = 3). (D) ChIP assay 
of c-Rel to endogenous IL-1β promoter in IFNγ/LPS-stimulated RAW264.7 
cells treated with AS2677131 (1, 10, 100 nM), inactive (100 nM), or DMSO. 
Quantification was performed as described above. 
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Fig. 15. 
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Fig. 16. AS2795440 prevents development of AIA. AIA was induced by a 
subcutaneous injection of CFA at day 0 and treated with AS2795440 (1, 3, 10 
mg/kg) or vehicle from day 1 to 24 (control; n = 10/group, AS; n = 5/group). (A) 
Time course of changes in paw volume in AIA or normal rats treated with 
AS2795440 or vehicle. The bar graph indicates values at the end of the study 
(day 25). (B) Body weight of AIA or normal rats at day 25. (C) Histological 
changes in joint from AIA and normal rats treated with AS2795440 or vehicle. 
Representative images (HE staining) are shown. Clinical scores were 
calculated for bone destruction, cartilage destruction, synovial thickening, 
and inflammatory cell infiltration. Values are expressed as mean ± S.E.M. 
(D) Expression levels of CD62L on CD3-CD45RA+ B cells in whole blood from 
AIA or normal rats treated with AS2795440, vehicle (blue), or normal (grey). 
(E) Percentages of CD3-CD45RA+ CD62Llow B cells in whole blood from AIA 
or normal rats treated with AS2795440 or vehicle. Values are expressed as 
mean ± S.E.M. Significant differences between AS2795440 and 
vehicle-treated (CT) groups: *: p < 0.05, **: p < 0.01, ***: p < 0.001 (Dunnet 
multiple comparison test) 
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Fig. 16. 
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General discussion 
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   To elucidate the immunological mechanisms of chronic inflammation and 
identify potential targets for novel anti-inflammatory drugs, in this study, I 
have focused on the intracellular signaling pathway regulating 
proinflammatory cytokine production in macrophages, because it has been 
reported that many biologic drugs, which can neutralize inflammatory 
cytokine activity, show excellent therapeutic effect on various chronic 
inflammatory diseases [2-4]. However, biological therapy is generally 
expensive and inconvenient to administer, and therefore I have screened and 
identified the small molecule inhibitors for two different targets, p38 MAPK 
(Chapter I) and PIKfyve (Chapter II), which have crucial roles in the 
inflammatory responses, including proinflammatory cytokine production in 
activated macrophages/monocytes and dendritic cells. This study has also 
revealed some roles of p38 MAPK and PIKfyve in the development of chronic 
inflammation by analyzing the pharmacological profiles of the newly 
identified inhibitors. 
   In the first chapter, I screened a small molecule inhibitor of p38 MAPK 
that is responsible for the production and activation signal of 
proinflammatory cytokines such as TNFα, IL-1β, and IL-6, and a novel p38 
MAPK inhibitor, AS1940477 was identified. Functional characterization 
regarding the anti-inflammatory properties of AS1940477 in both in vitro 
and in vivo has indicated that its potency and selectivity against p38 MAPK 
is superior to those of previously reported p38 MAPK inhibitors (Fig. 2-7, 
and Table 1-2). Especially, it is remarkable that AS1940477 can reduce the 
production of LPS-induced TNFα and IL-6 production in rats at doses below 
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0.1 mg/kg (Fig. 6A-C) and its inhibitory effect lasts for 20h after oral 
administration (Fig. 7). Following completion of the current study, 
Toru-Asano et al. also reported that AS1940477 prevented the development 
of experimental arthritis in rats [73], which is supporting that the inhibition 
of p38 MAPK may be useful for the treatment of chronic inflammatory 
diseases. On the other hand, some clinical studies on p38 programs showed 
that early suppressive effect on CRP was not sustained and rebounded by 2-4 
weeks, and others also have the opinion that it is preferable to combine 
inhibition of p38 with other targets in parallel inflammatory signaling 
pathway to achieve the desired efficacy in chronic inflammatory disease [74]. 
In that regard, it may be necessary to obtain further clinical data using 
potent and high selectivity inhibitors such as AS1940477. 
   In the second chapter, I firstly screened small molecule inhibitors for the 
production of IL-12p40 in IFNγ/LPS-stimulated macrophages, and identified 
two potent and selective IL-12p40 production inhibitors, AS2677131 and 
AS2795440. Functional characterization has indicated that these compounds 
show inhibitory activity against proinflammatory cytokine production 
(IL-12p40, IL-6, IL-1β but not TNFα) and BCR-mediated B cell activation 
(Fig. 9 and 10), and a significant preventive effect was also confirmed on 
experimental arthritis in rats (Fig. 16). Furthermore, molecular biological 
analysis using photoreactive linker-conjugated probes has shown that 
PIKfyve is a direct target and selectively regulates the binding activity of 
c-Rel to the promoter of proinflammatory cytokines, including IL-12p40 and 
IL-1β (Fig. 12-15 and Table 8-10). These results indicate that PIKfyve is a 
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key signaling molecule for proinflammatory cytokine production and 
BCR-mediated B cell activation, but this study has unveiled only a part of 
the immune regulatory mechanism of PIKfyve. It remains unknown whether 
PIKfyve directly or indirectly controls c-Rel activity and whether the 
mechanisms of proinflammatory cytokine production and B cell activation 
are mediated by membrane trafficking or autophagy system. 
Mammalian PIKfyve that was originally discovered from mouse 
adipocytes in screening as one of transcripts like GLUT4 transporter 
controls pleiotropic expression cell function. The best-characterized role of 
PIKfyve is membrane trafficking pathway, especially, many studies on 
endosome formation have been reported. On the other hand, there has been 
no major report on PIKfyve involvement in immune system until recently, 
although PI3K, one of the family protein regulating PI metabolism same as 
PI5K including PIKfyve, is known to be an important molecule in immune 
system [75]. The report of Cai X et al in 2013 showed that PIKfyve was the 
target of apilimod, an IL-12/IL-23 inhibitor, and it was firstly revealed that 
PIKfyve contributed to the inflammatory response [60]. Thereafter, several 
studies has been reported that PIKfyve is involved in TLR-mediated type I 
IFN production [76], allergic inflammatory reaction [77], and immune 
system in neutrophil [78], but understanding of molecular mechanisms 
including cytokine production is still insufficient. The findings in this study 
that PIKfyve regulates proinflammatory cytokine production via c-Rel are 
consistent with the previous reports that deletion of c-Rel in macrophages 
selectively decreased IL-12p40 production [42], which has greatly 
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contributed to the correct understanding of the mechanism of chronic 
inflammation.  
   In conclusion, the current study has demonstrated that p38 MAPK and 
PIKfyve play key roles in the development of chronic inflammation, and the 
inhibition of their kinase activity by novel small molecule inhibitors 
(AS1940477, AS2677131, and AS2795440) could be a new therapeutic 
approach for treating chronic inflammatory diseases. It is also expected that 
new molecules as anti-inflammatory drug targets will be found in future 
from PIKfyve-c-Rel pathway. 
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